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ABSTRACT 
ANALYSIS AND EVALUATION OF COMMUNITY PHARMACISTS 
INTERVENTIONS IN THE RANDOMISED EVALUATION OF 
SHARED PRESCRIBING FOR ELDERLY PEOPLE IN THE 
COMMUNITY OVER TIME (RESPECT) STUDY 
Key words: RESPECT study, Elderly, Pharmaceutical care, Clinical Panel, Community Pharmacist 
intervention, General practitioners. 
 
The impact of the pharmacist in elderly patient healthcare management is 
developing. In our study, the interventions made by community pharmacists in the 
RESPECT study (Randomised Evaluation of Shared Prescribing for Elderly people in 
the Community over Time) were analysed and evaluated. 
In our study, the study sample was chosen according to specific criteria. The 
outcomes of these pharmacist interventions were measured by a clinical panel which 
scored and categorised each intervention into one of five categories. The study also 
investigated the percentage of interventions implemented or not implemented by GPs. 
In our study, initially 398 patients and of these 52 were excluded because their 
files did not contain the entry criteria information, leaving 346 patients who were 
identified with a mean (SD) of 8.9 (3.3) pharmaceutical care plans which contained 
mean (SD) 8.2(7.2) pharmaceutical care issues. Of these 43% were males and 57% were 
females with a mean (SD) age of 81(3.7) years. There were many missing data about 
drugs prescribed due to poor documentation by community pharmacists in the 
RESPECT study particularly at post study period (T5). The mean (SD) for all drugs 
prescribed was 35.9 (12.38) for each patient and for the whole study period including 
the post period (T5). 
In our study a total of 2879 individual pharmaceutical care issues were 
identified. A clinical panel judged that 43% of the interventions prevented harm, 31% 
improved the efficacy of management, 3% were detrimental to the patient’s 
management plan, 12% only provided information and there was insufficient 
information to make a decision on the remaining 11%. For the classifications prevented 
harm to the patient and improve efficacy of management,  the panel gave a score of 7 or 
more to 264 and 103 respectively which were classed as potential prevented hospital 
admissions. The outcome of 1628 could not be determined from the data and the 
pharmacist did not intervene on 361 occasions. Of the remaining 890 (30.9%) GPs 
accepted 715 and did not accept 175.   
The cost effectiveness of providing pharmaceutical care to older people by 
community pharmacists could be estimated (£620,000) by calculating reduction in 
expenditure of hospital admissions. In addition, there would be the possibility of 
reduced pressure on other NHS resources such as availability of hospital beds.  
The involvement of a clinical pharmacist in elderly patient health care, within the 
setting of a community pharmacy, provided positive healthcare outcomes and therefore 
should be encouraged in line with the new white paper for England "Building on 
strengths-delivering the future" (2008). The study emphasises the importance of revising 
the nature and period of postgraduate training for community pharmacists who are going 
to provide pharmaceutical care for elderly patients. This raises the possibility of 
specialised competency based postgraduate training for community pharmacists with a 
special interest in the care of older people (PhwSI). This would enable community 
pharmacists practising as generalists to become advanced practitioners in the specialist 
clinical area of older people and ensure a consistent level of service for elderly patients in 
line with government expectations. 
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CHAPTER 1 
INTRODUCTION 
 
 
 
 
 
 
 
 
  2 
Background to the study of older people 
Older people make up 16% of the population in the UK, Figure 1 and appendix A 
shows that the breakdown of the year groups from 65 years to over 85 years), but, they 
consume about 43% of medication prescribed in England and Wales. In England, only 
21% of the population is over 60 years old and they receive 56% of prescriptions 
dispensed (Lowe et al., 2000), (Lenaghan et al., 2007). In Scotland, the number of 
elderly people of 75 and over is expected to rise by 61% in 2027 (G.R.Scotland, 2003). 
The National Health Service (NHS) in the UK spent more than 40% of its budget on 
medications to care for elderly patients (Wong et al., 2004). 
Figure 1 Estimated percentage growth of elderly in United Kingdom 
 (Source: Government Actuary Department, 2002) 
 
 
 
In the united States, people older than 65 years old totalled 3 millions in 1990 and will 
reach 50 million by 2020 and they use 30% of health care resources at the time of study 
by Abrams, (1990). 
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Increasing detection of the burden associated with iatrogenic disease has led to 
international interest in how best to promote patient safety, particularly in the elderly  
(Cresswell et al., 2007).   
The pharmacokinetics and pharmacodynamics are altered with advanced age, and 
consequently elderly people have a greater susceptibility to drug-related problems. 
Furthermore, polypharmacy and iatrogenic disease are more prevalent in aged people.  
 In these age group, along with cognitive impairment and physical function 
weakness, these factors may lead to their failure to use medication appropriately and 
greater risk of medication-related problems (Taylor and Harding, 2001). 
Pharmaceutical care issues (PCIs) or drug related problems ( DRPs) are prevalent 
in elderly patients in the community and in the hospital and are responsible for a high 
rate of hospital admissions among the elderly patients (Cunningham et al., 1997).The 
high tendency for PCIs in elderly patients may result also from age-related 
physiological changes, the presence of multiple chronic diseases and the types and 
numbers of prescription and non-prescription medications (OTC) they consume 
(McLeod et al., 1997). 
The Nuffield Report (1986), first highlighted that Community pharmacists were 
gradually extending their roles into more clinically-oriented services (Nuffield 
Foundation, 1986). Many studies support extending the roles of community pharmacists 
due to their positive contribution in detecting and reducing the impact of  PCIs (Buurma 
et al., 2004). In 1992, the Royal Pharmaceutical Society of Great Britain ( RPSGB) and 
the Department of Health (DOH) published a report on the extended role of community 
pharmacy to include, in addition to the advisory role, a domiciliary service to elderly 
patients which includes monitoring the effectiveness of patient therapy and the disposal 
of unwanted medicines (Harding and Taylor, 1997). In addition the RPSGB in 1997 
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reported that UK community pharmacists should have an essential role in effective 
medicines management for elderly people (Needham et al., 2002). 
In May 2000, research funders, including the Department of Health, The Medical 
Research Council, The Biotechnology Biological Sciences Research Council and the 
Engineering and Physical Sciences Research Council announced plans to develop a 
coordinated approach to ageing research by forming the Ageing Research Funders 
Forum (Wong et al., 2004). Subsequently, in March 2001, the Department of Health 
released the National Service Framework (NSF) for older people (Adam, 2001). Its 
main aim was to make sure elderly patients gain maximum benefit from their medicine 
with the purpose of maintaining or improving their quality or duration of life (NHS-
Survey, 1998).  
Community pharmacists, with their clinical skill, knowledge of medicines and 
ease of accessibility for the elderly, can have a significant role in providing 
pharmaceutical care for elderly patients (Black and Kinsey, 2007). Provision of specific 
pharmaceutical care services by community pharmacists such as medication reviews 
and domiciliary visits can ensure that the potential problems do not lead to poor 
outcomes and furthermore, provision of  a carer to assist an elderly dependent would 
ensure prescribed medication instructions are followed (Taylor and Harding, 2001). 
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1.1.1. Challenges for elderly prescribing for elderly 
 
One of the major challenges for elderly prescribing is the age–dependent changes 
in drug distribution and sensitivity. The most important pharmacokinetic changes 
however are usually combined with ageing and are due to the decline in renal and 
hepatic functions (Cresswell et al., 2007).  
Water content in elderly decreases and the fat content rise, therefore volume of 
distribution (Vd) and elimination half life of lipophilic drugs is increased and this 
results in prolonged duration of effect. Furthermore, a reduction in homeostatic 
mechanisms and receptor stimulation usually associated with ageing leads to the 
responses to drugs being often stronger than in younger people for many drugs such as 
diazepam (Armour and Carins, 2002) (Figure 2). 
Figure 2 Factors contributing to drug related problems in elderly patients  
In addition, many elderly patients cannot cope with the complexity of medication 
regimens through reduced visual and cognitive impairment and memory loss. All these 
factors contribute to the increased possibility of medication error (Taylor and Harding, 
2001), Therefore, health care providers should understand the influence of body 
composition change in older people before prescribing any medications. 
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1.1.2. Inappropriate prescribing for elderly patients 
 
Inappropriate prescribing occurs commonly among elderly people and a critical 
evaluation of literature concluded that up to 51% of drugs for elderly patients were 
overused and up to 90% were misused (Hanlon et al., 1996). 
 
 
 
 
 
Figure 3 Inappropriate medications use types 
 
In the UK, inappropriate medication use (IMU) in the community becomes a 
common and current problem, particularly in patients with multiple medication therapy. 
IMU can be divided into three classes: Underuse (e.g. sub-therapeutic dosage, poor 
adherence by patient), overuse (e.g. not tailoring doses in elderly patients or patients 
with renal failure) or misuse (e.g. failure to recognise potential drug interactions) as 
shown in Figure 3. 
IMU can lead to negative outcomes, particularly (1) adverse reaction and (2) poor 
compliance with medications. Also, it usually coupled with (3) unnecessary medical 
expenditure and (4) Hospital admissions and (5) readmissions. These have been scored 
as the five most important issues in care for elderly people (Hanlon et al., 1996). 
Recently, many studies have investigated the methods to improve medication 
prescribing. One method known as face-to-face educational outreach visits by 
physicians or pharmacists supplemented by brief graphic print materials has been shown 
to be effective in reducing inefficient prescribing or contraindicated drug prescribing 
(Hanlon et al., 1996, Al-Rashed et al., 2002, Freemantle et al., 2002). 
51% 
Overuse 
Inappropriate use of 
medications 
 
Underuse Misuse 
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Inappropriate medication use (IMU) can be measured by using either explicit or 
implicit methods. Drug Utilisation Evaluation (DUE) and Drug Utilisation Review 
(DUR) are examples of explicit methods. For explicit methods, little clinical knowledge 
and judgement are used. In contrast, implicit methods such as medication 
appropriateness index (MAI) need clinical judgement to measure IMU (Kassam et al., 
2003). 
1.1.3. Polypharmacy in elderly patients  
 
Ageing can lead to a greater prevalence of chronic health conditions which 
increases medication use (polypharmacy) and health care system costs. The 
consequences of polypharmacy are non-adherence, adverse drug reaction, drug-drug 
interaction (Figure 4), increased risk of hospital admission, health care costs and 
medication errors (Lyra et al., 2007, Kennerfalk et al., 2002). 
 
 
 
 
 
 
Figure 4 Correlation between prevalence of adverse drug reactions and polypharmacy. 
(Source: University of Kansas Medical Canter / Centre on Aging). 
 
In the UK, data are currently collected on all prescriptions dispensed and this 
shows that elderly patients receive 35-40% of all drugs prescribed. Moreover, between 
1977 and 1988, prescription items increased by 52% in people aged over 65 (Thomson 
and Crome, 2002). Pharmaceutical counselling, medication discharge information 
summary (MDIS) and medicine reminder to elderly patients with polypharmacy have 
been shown to improve their understanding of instructions and their compliance (Al-
Rashed et al., 2002). 
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1.2. RESPECT study 
1.2.1. Background of the RESPECT study  
 
RESPECT, which stands for Randomised Evaluation of Shared Prescribing for the 
Elderly in the Community over Time, was funded by the Medical Research Council and 
five Primary Care Trusts (PCTs) in East and North Yorkshire. The basis of the 
RESPECT trial is that community pharmacists should have essential roles to conduct 
the medication review for elderly patients (Wong et al., 2004). 
Several reasons encouraged researchers to carry out the RESPECT study 
including the growing number of elderly population in the UK. In addition, the UK 
government has been encouraging the community pharmacist’s role as an expert in drug 
therapy to have a crucial role in providing pharmaceutical care to elderly people shared 
with the other health care providers. The problem addressed in the RESPECT study was 
the inappropriate therapy for the elderly. It also highlighted the high cost of drugs 
prescribed for elderly people and the positive impact of community pharmacists in 
reducing that cost (Wong et al., 2004). 
1.2.2. Aims of RESPECT trial 
 
The main aims of RESPECT are to investigate the impact and cost effectiveness 
of pharmaceutical care (PC) which is provided by community pharmacists for the 
elderly (Wong et al., 2004). 
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1.2.3. Research questions of the RESPECT study 
 
1. Was pharmaceutical care (PC) for elderly patient who are living in the 
community effective in improving the quality of prescribing? 
2. Did pharmaceutical care improve patient knowledge and patients' compliance 
and reduce adverse effects? 
3. Was quality of life improved? 
4. Was pharmaceutical care cost effective? (Wong et al., 2004). 
1.2.4. Rationale for choosing elderly people in RESPECT study 
 
The UK is facing a growth in the number of elderly patients (Armour and Carins, 
2002). 80% elderly aged 75 take at least one prescribed medication and 36% take four 
to five. More than half of all prescriptions are written for all people over the age of 60 
and the NHS spent 40% of its budget on people over this age (Wong et al., 2004). 
1.2.5. Method of the RESPECT study 
 
• The RESPECT study was set up according to Figure 5 and data were collected 
from patient completed questionnaires. These data were used to evaluate the 
impact of the RESPECT trial on appropriateness of medication prescribed, by 
using the MAI (Medication appropriate index). 
• The RESPECT study is a randomised controlled trial in which each participant 
receives an intervention and each participant acts as his/her own control. 
Furthermore, each primary care trust which was used in the randomisation 
process was asked to work within their cluster of surgeries to select the patients 
recruited to the study (Wong et al., 2004). 
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• Patients recruited to the study had to visit a pharmacy and general practitioners 
within the same primary care trust. Furthermore, participant’s patients were 
encouraged to obtain their refill medications during the trial from the same 
pharmacy.  
• Until the start of the trial, pharmacists were blind to the study and did not know 
which patients were recruited for the trial and, so they provided their usual 
services. 
• All pharmacists who participated in this trial completed their training for the 
provision of pharmaceutical care. This training consisted of two evening 
workshops with a pre-workshop task, which included case studies covering the 
medical conditions which often affect elderly patients. 
• For the purpose of effective communication and to reduce barriers, two GPs and 
their practice managers were invited to complete joint training with their 
community pharmacist colleagues. 
• 67 community pharmacies were selected to participate in the trial but only 62 
provided pharmaceutical care for recruited patients. The 90 GPs were randomly 
selected from a list of those who had expressed an interest and this represented 
24 surgeries. 
1.2.6. Patient Inclusion and Exclusion Criteria’s 
 
1.  In total 760 patients were recruited and were all aged 75 years or older with 
five or more repeated medications, excluding any drug used when required (i.e. 
PRN). 
2. Patients included in the RESPECT trial should live at home and this excluded 
patients who lived in residential or nursing care establishments. 
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3. Patients recruited in the RESPECT study should be well oriented in time and place      
and able to consent to participate in this trial. 
1.2.7. Time scale of the RESPECT study 
 
Example of the time scales for the RESPECT study in one of primary care trust 
involved as follows: 
1) Recruit: Recruitment period (8 months). 
2) TM: Training and preparing materials (4 months + control period 3 months). 
3) Control: Control period (Different periods in different PCTs). 
4) M: Intervention period (for 12 months). 
      M3 (measure outcome at 3 months from the start of intervention), 
      M12 (measure outcome at 12 months from the start of intervention). 
5) Post period (measure outcome at 36 months from the start of intervention). 
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Figure 5 RESPECT Study Design 
(Adapted from Wong et al., (2004)) 
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In the RESPECT study, community pharmacists provided PC by establishing a 
relationship with patients, collecting, synthesising and explaining relevant information 
on patients disease and drugs; defining and grading any drug-related problems and 
establishing therapeutic plans to solve them and describe possible alternative treatments 
(Wong et al., 2004). 
Drug-related problems (DRPs) also known as pharmaceutical care issues (PCIs) 
types investigated in RESPECT were failure to receive drug, untreated indication, 
improper drug selection, sub-therapeutic dose, overdose, adverse drug reaction (ADR), 
drug used without valid indication and drug interaction (Wong et al., 2004). The 
intervention types were education about drugs used, withdrawing unwanted drugs, 
introducing a type of compliance aid (for instance dosette boxes and reminder chart), 
updating pharmaceutical care plan (PCP), monitoring the outcome monthly at least and 
following up (Wong et al., 2004). The primary outcome measure in this study is MAI 
(medication appropriateness index), Secondary measures are knowledge, compliance 
and concordance of the patient, and the economic measure used is cost of treatment for 
NHS or patient (Wong et al., 2004). 
1.2.8. Data collection and outcome measures of the RESPECT study 
 
•  The UK MAI was used to answer the main question of the RESPECT trial, which 
was whether the study was effective in improving the quality of prescribing. 
• The secondary outcome measures included improved patient knowledge,      
compliance and concordance, practice-reported adverse effects and self assessed 
outcomes. 
• Economic evaluation included all aspects of NHS costs including time spent for 
provision of PC and whether PC reduced patient visits to GP and nurse. 
• Data also was collected from patient completed questionnaires and patient medical 
records (PMR). 
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1.3. Research questions of this study carried out 2007/08 
       Our study was to categorise, analyse and evaluate community pharmacists' 
interventions in the RESPECT study. It was to investigate the role of community 
pharmacists in the community in improving prescribing among GPs through their 
recommendations on elderly patients’ treatment, monitoring, counselling or medication 
review. 
The questions that this research will address include: 
1. Were community pharmacist interventions in the RESPECT trial for the elderly 
effective in improving their health care outcome for them? 
2. Were community pharmacist’s recommendations accepted by GPs? 
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1.4. Thesis Structure 
The thesis is organised as follows: 
   Chapter 1 has been presented as a general introduction to the problem of 
inappropriate prescribing for elderly patients and the impact of community pharmacist 
interventions in improving inappropriate prescribing for such patients. It also clarifies 
the extended role of community pharmacists and why the RESPECT study and this 
research were carried out. As this study follows on from the RESPECT trial, the second 
part of chapter 1 explains and gives some background about the RESPECT study. 
 In Chapter 2, there is an extensive literature review on the issues in chapter 1 and 
other related issues, which include pharmaceutical care of older patients, role of the 
community pharmacist in improving prescribing for the elderly, polypharmacy and 
adherence. The second part of the chapter 2 focuses on one of the main objectives of the 
study which is the classification of the pharmaceutical care issues (PCIs) and the 
categorisation of pharmacist interventions during their provision of pharmaceutical care. 
Chapter 3 is the most important part of the thesis which describes our study of 
the analysis and evaluation of community pharmacists’ interventions in the Randomised 
Evaluation of Shared Prescribing for Elderly people in the Community over Time 
(RESPECT) study. 
Chapter 4 is general discussion and conclusion of  our study. 
  
 
 
 
 
 
 
 
CHAPTER 2 
LITERATURE REVIEW
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2.1. Pharmaceutical care (PC) 
2.1.1. Introduction  
 
 The history of pharmaceutical care (PC) has passed through several stages. In 
1986, The Nuffield Report highlighted the new responsibilities of community 
pharmacists in the future as being  more clinically oriented (Nuffield Foundation, 1986). 
In 1987, PC was described by Hepler as a covenantal relationship between the patient 
and the pharmacist. He suggested that the pharmacist should accept more responsibility 
for medication use control, as authority would support that.  
2.1.2. Definition of pharmaceutical care 
 
 Pharmaceutical care was first defined by Mikeal et al., (1975) as the care a given 
patient requires and receives which assures safe and rational drug use. In 1989, Hepler 
defined PC as the provision of drug therapy for the purpose of achieving definite 
outcomes which improve a patient’s quality of life (Cippole et al., 1998). The term 
pharmaceutical care was also defined by Hepler and Strand in 1990 as the services 
which are provided to reduce drug-related morbidity and mortality, and the cost of care, 
by the process of identifying, resolving and preventing drug-related problems 
(Appendix W) (Cippole et al., 1998). They proposed a system of pharmaceutical care, 
where the doctor continues to take the ultimate role in patient care and the pharmacists 
are responsible for moderating their drug care. In order to do that, pharmacists co-
operate with doctors, patients and /or carers in designing, implementing and monitoring 
a pharmaceutical care plan (PCP) which aimed to achieve specified therapeutic 
outcomes (Needham et al., 2002). 
 Hepler and Strand., (1990) redefined PC as " the responsible provision of drug 
therapy for the purpose of achieving definite outcomes that improve a patient quality of 
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life. These outcomes are (1) Cure of disease, (2) Reduction or elimination of a patient 
symptoms, (3) Arresting or slowing disease process, or (4) Preventing a disease or 
symptoms. In 1998, the International Pharmaceutical Federation (IPF) defined PC as " 
the responsible provision of drug therapy for the reason of achieving definite outcomes 
that improve a patient’s quality of life". It is a collaborative process that aims to prevent 
or identify and solve medicinal product and health-related problems (Federation-report, 
1998). 
  Cipolle et al., (1998) defined pharmaceutical care as a practice in which the 
practitioner takes responsibility for patient drug-related needs and is held accountable 
for this commitment. A new definition of PC by Fischer et al., (2002) is a programme in 
which pharmacists work directly with patients to assess, monitor and modify their 
pharmaceutical regimen.  
2.1.3. Development of pharmaceutical care 
 
Since the introduction of PC by Hepler and Strand, (1990), educators and 
pharmacy organisations, institutions and pharmacists have adopted the PC philosophy 
for pharmacy practice. 
In 1991, Hepler introduced the concept of programme evaluation for clinical 
pharmacy services and made recommendations to improve research design (Kennie et 
al., 1998). 
In 1992, the Royal Pharmaceutical Society of Great Britain (RPSGB) and the 
Department of Health (DOH) released the joint working party report entitled 
Pharmaceutical Care: " the future roles for community pharmacy" to include 
therapeutic drug monitoring (TDM), domiciliary visiting, health promotion, repeat 
dispensing and clinical audit (Hawksworth et al., 1999). In 1994, the RPSGB developed 
guidelines for managing the change in community pharmaceutical services and to 
extend their services to house-bound patients, disposal of unwanted medicines, health 
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screening, patient referrals to GPs and other health care professionals and professional 
advice i.e. smoking cessation and OTC medicines (Hawksworth et al., 1999). 
In 1994, Hepler discussed cooperation with other pharmacists, physicians, 
nurses and carers as part of the PC. This means a change in pharmacy practice 
behaviours of the pharmacist which involves solving, referral, monitoring and 
documentation of problems (Hawksworth et al., 1999). 
Cippole et al.,(1998) said that the philosophy of PC includes, rather than general 
principles of achieving social needs, taking a patient-centred approach and caring for 
patient-drug related problems. This time the focus is on a new approach which is to 
establish specifically three different responsibilities: 
• To make sure the patient drug therapy is appropriately indicated, the most effective, 
the safest as possible and able to be taken as intended. 
• To detect, solve and prevent any pharmaceutical care issues. 
• To ensure the goals of treatment are met and optimal outcomes are achieved. 
Guignard et al., (2007) explored contemporary pharmacists roles and concluded they 
not only dispense drugs but also review the completeness and accuracy of the 
prescription, collaborate with prescribers to optimise therapy, and provide counselling 
and information to patients. Their role in achieving optimal therapeutic results has been 
recognised. They can detect prescription-related problems which can be corrected, 
avoiding complications for the patient and making substantial savings. 
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2.1.4. Pharmaceutical care and social needs 
 
Pharmaceutical care (PC) consists of different elements; it begins with the 
question of what is social need and what are the patients needs with a patient-centred 
approach to achieve this need (Cippole et al., 1998). This was also identified by 
Hawksworth et al., (1998).  
In order to meet it, all professionals must apply and develop their knowledge and 
skills to provide a service, for example manufacturing to compounding and dispensing 
to clinical pharmacy, in an era of pharmaceutical care. This meant that pharmacy 
practice evolved from medications’ dispensing to a patient-oriented profession with the 
aim of optimising the use of medicines. 
In PC practice, the pharmacist minimises medicinal management problems such 
as morbidity and mortality by attending to patient need. The first important elements in 
PC practice philosophy is that the pharmacist’s essential responsibility is to contribute 
to meeting society needs for appropriate, effective, safe and convenient drug therapy 
(Cippole et al., 1998). 
In the UK, PC or medicines management highlights the role of pharmacists in 
providing safe and effective medicinal use and the two terms have been used 
interchangeably to describe the process of helping patients get the best from their 
medicines. However, medicines management involves not only pharmacists, but also 
other health care providers and patients, and has been used in many documents of the 
pharmacy plan in the NHS (Simpson et al., 2001). 
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2.1.5. Pharmaceutical care with patient-centred approach 
  
The patient-centred approach considers the patient as a whole individual, that is 
health care needs generally and drug-related problems specifically, with the patient as 
superior in care planning and as the ultimate decision maker. A patient centred-
approach defines the responsibility of the pharmacist as not just providing the drug for a 
particular disease but also with regard to the patient expectation and understanding of 
his/her drug and illness. This approach encourages the pharmacist to continue providing 
PC until all the patient needs are met. Hepler (1998) further described pharmaceutical 
care as " a covenantal relationship between a patient and a pharmacist in which the 
pharmacist performs drug use control roles (with appropriate knowledge and skill) 
governed by the awareness and commitment to the patient interest (Cippole et al., 1998). 
 2.1.6. Therapeutic relationship 
 
Hepler and Strand (1990) used the term covalent to describe the relationship 
between the pharmacist and the patient. This relationship is essentially the agreement 
for all concerned to work together for the resolution of all medicinal management 
problems. The pharmacist agrees to evaluate the patient needs, to successfully meet 
these needs and to follow up to ensure that effective, good interventions take place. The 
patient agrees to provide accurate and complete information to the pharmacist and to 
play an effective role in the care provided. This means the patient agrees to set goals 
and to provide the necessary information required for beneficial care (Hepler and Strand, 
1990). 
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2.1.7. Concordance, compliance and adherence 
 
There are three terms in common usage: compliance, adherence and 
concordance. These are now used interchangeably, which has generated some confusion. 
 Compliance is defined as the extent to which the patient’s action matches the 
prescribers' recommendations (Armour and Carins, 2002). However, its use is declining 
as it implies lack of patient involvement.  
Adherence is defined as the level to which the patient’s behaviour matches 
agreed instructions from the prescriber and it is an attempt to highlight that the patient is 
free to decide how closely the drug regimen is followed (Armour and Carins, 2002).  
Concordance is a relatively recent term predominantly used in the UK. Its 
definition has changed over time from one which focused on the consultation process, in 
which doctor and patient agree therapeutic decisions (Horne et al., 2006). Concordance 
was encouraged to address the shared interaction between patients and their physician to 
arrive at collaborative agreed goals (Bissell et al., 2004). Blenkinsopp (2001) defined 
the concept of concordance as giving the patients greater involvement in decisions about 
their own treatment. 
In 1997, the RPSGP set up a collaborative project with the Department of Health 
which published a report From Compliance to Concordance. In the same year , the UK 
government began to introduce the term concordance into its health policies and 
committed funding to its development and implementation  (Blenkinsopp, 2001). 
2.1.8. Responsibilities of pharmaceutical care pharmacist 
 
Expanding the role of the pharmacist in patient care could improve the safety 
and efficacy of drug therapy (Fischer et al., 2002). Community pharmacy in health care 
delivery has received much attention by the government and the role has been changed 
by the deregulation of prescribing restrictions which allows a greater range of products 
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to be sold without a doctor’s prescription. This makes pharmacists feel that they are able 
to offer a range of services in addition to their traditional dispensing role involving 
pharmaceutical advice, health advice and even some clinical services such as blood 
pressure measurement and cholesterol monitoring (Jones et al., 1997). 
Any community pharmacist who provides PC is responsible for ensuring that all 
indications for drug therapy are being treated effectively by medication. This can be 
accomplished by identifying, resolving and preventing medicinal management problems. 
Also, ensuring that patient is able to comply with medication instructions and a care 
plan in order to produce positive patient outcomes (Appendix W).  
The cornerstone in providing pharmaceutical care is to establish the relationship 
between the patient and practitioners and the primary aim of the first discussion with 
patients is to determine what they understand about their drug therapy, what their 
expectation is about treatment and what their concerns are about medications. This 
information allows pharmacists to translate patient concern and expectation into a 
problem solving format and to address patients’ requirements using their knowledge, 
skill and experience (Cippole et al., 1998) (Table 1). 
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Table 1 Translation of drug-related needs into pharmaceutical care issue 
Source: (Cippole et al., 1998) 
 
Patient 
expression 
Drug-related 
needs 
Drug-therapy problems 
Understanding Indication • Add. new drug 
• Unnecessary drug (assess 
drugs  indications) 
Expectation Effectiveness’ • wrong drug used 
• Dosage is low 
Concerns Safety • Adverse  reaction 
• Dose is high 
Behaviour Compliance •  Compliance. 
 
 It is most important that the responsibilities require the pharmacists who are 
providing PC to be prepared and qualified to make decisions which can lead to positive 
outcomes and promote consistent, systemic, comprehensive and well reasoned results. 
2.1.9. Medicines management (MM) 
 
Medicines management (MM) is a general term that covers all aspects of 
medication use including pharmaceutical care (PC). MM involves not only pharmacists 
but also patients and health care professionals. The National Prescribing Centre, (2002) 
defined Medicines Management (MM) as a system of processes and behaviour which 
determines how medicine is used by patients.  
Tweedie, (2001) defined MM as " the systemic provision of drug therapy 
through establishing a relationship between patients and professionals to deliver best 
outcomes at minimised cost.  
In summary, features of MM include cooperation between participants, 
minimised cost, excellence, clinical skill and finally concordance. 
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2.2. Pharmaceutical Care for Elderly patients 
2.2.1. Appropriateness of prescribing 
 
Inappropriate prescribing can be defined as over or under use of medications and 
the rationale of prescribing is to prescribe the right drugs for the right patient at the right 
time with consideration of relative costs.  
Inappropriateness of prescribing becomes a major factor in non-compliance for 
elderly patients due to the multiple drugs prescribed for them and also pharmacokinetic 
and pharmacodynamics change in older people. According to some researchers, there 
are three ways to measure inappropriate prescribing: drugs to be avoided, drug 
utilization reviews and applying explicit criteria (Kassam et al., 2003). 
Brook, (1994) developed explicit methods to measure the appropriateness of 
prescribing with a list of specific clinical indications developed by using a list of the 
indications and a literature review rated by study panel for appropriateness on a scale of 
1 to 9 . 
Shelton et al., (2000) used purely implicit tools (without using specific criteria) 
the programme having five open goals. These included : (1) To reduce total number of 
medications, (2) To adjust doses to appropriate levels for an elderly patient, (3) To 
increase compliance, (4) To review social and economics aspects of the regime and 
finally (5) To encourage non-drug therapy. The disadvantage of implicit criteria is that 
they have poor reliability which is exactly the limitation of implicit tools. Therefore, 
Shelton et al., (2000) devised and reviewed a tool which has two approaches, explicit 
and implicit, which is the medication appropriateness index (MAI). With this tool the 
reviewer is required to evaluate each drug in six ways which include drug allergy, 
dosage, drug schedule,  presence of any contraindications’ /indications, drug-drug 
interaction and duplication.  
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In the UK, the most important study for appropriateness has been conducted  by 
Cantrill et al., (1998) which has focused on disease management not patient 
management; the indicators they used were based on GP medical records. The study 
encourages using both explicit and expert review to allow implicit judgements to be 
made. In the RESPECT study, the primary outcome measure of appropriateness was the 
"Medication Appropriate Index" (MAI) to evaluate the effect of PC in terms of 
appropriateness of prescribing to older people in the UK. 
 2.2.2. Elderly patients and pharmaceutical care issues (PCIs) 
 
The elderly are a patient population who could particularly benefit from PC 
provision as they are at greater risk of experiencing significant PCIs such as 
inappropriate prescribing, non-compliance with prescribed medication and adverse drug 
reactions / interactions leading to a decrease in health- related quality of life (Crealey et 
al., 2003).  
 
 
Figure 6 Interaction between PCIs, acute illness and Polypharmacy 
The major cause of PCIs in elderly patients is multi-drug therapy (Polypharmacy) 
because drugs are usually prescribed more frequently than for younger people and the 
rate of prescribing appears to be increasing all the time (Figure 6). In the UK, data 
currently collected revealed that 35-40% of all drugs prescribed were for elderly 
patients (Thomson and Crome, 2002).  
↑Pharmaceutical 
care issues  
Acute illness 
Polypharmacy 
↑Hospital 
admissions 
frequency 
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The main consequences of polypharmacy are non-adherence, adverse drug 
reactions and drug-drug interactions which increase risk of hospitalisation and health 
care cost and medication errors (Lyra et al., 2007). Polypharmacy combined with 
changes in pharmacokinetics and pharmacodynamics in older people makes them more 
susceptible to drug related problems (Cunningham et al., 1997, Vinks et al., 2006).
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2.2.3. Elderly patients and Adherence 
Patient adherence to prescribed medications has been shown to be low, 
particularly in patients with polypharmacy and long-term treatment (Krigsman et al., 
2007). Non-compliance is a major factor in morbidity and avoidable hospital admissions; 
it results mainly from a lack of patients understanding of their disease, its treatment and 
the failure to follow the regimen prescribed by the physician. This has been a problem 
historically and consistently researched in this age group. Interviews with 22 elderly 
patients revealed that only less than half could correctly name their medication, the 
prescribed doses and dosage intervals, and a quarter of them were definitely non-
compliant (Bouvy et al., 2003). 
Kirk, (1982) classified the reasons for non-adherence in older people into two 
categories: (1) patient factors, "such as dementia, impaired memory and cognitive 
flexibility, dependency on their family, limited access to transportation" and (2) 
Structural barriers, "such as language and ethnic barriers" . Furthermore, the complexity 
of the regimen notably decreases compliance; however, frequency of dosing seems to be 
a more important factor for compliance than the number of different medications taken 
at each dosing interval. Side effects may also cause non-compliance.  
Compliance is more likely if an illness has easily recognisable and unpleasant 
symptoms are relieved by following the physician’s recommendations. Furthermore, 
physician and family can improve patient compliance with encouragement, re-education 
and positive feedback. In a patient who is easily confused, compliance aids availability 
such as compartmentalised containers, medication calendars, and nomad tray and 
dossette box can help patient compliance. Furthermore, successful educational and 
suitable interventions which are often relatively short lived must be given repetitively 
(Kirk, 1982). Corlett, (1996) summarised the causes of non-compliance in elderly 
people and aids to improve elderly patient compliance as in Table 2. 
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Table 2 Non-adherence causes and methods to improve elderly patient compliance.  
 Source: Adopted  from (Corlett, 1996) 
Non-adherence causes Methods to improve patient compliance 
Not knowing how to administer medication Educating patients about disease and treatment 
Not understanding importance of drug 
treatment in managing disease 
Simplifying drug regimes, minimising number of drugs 
and frequency of doses 
Polypharmacy Using modified or controlled release preparations to 
decrease dose frequency. 
Side effects Involving carers in management of medication 
Forgetfulness Telling patients about common early side effects to which 
they may develop tolerance 
Impaired physical function Using drug diaries, calendars or medication chart 
 Using large print or jumbo labels on containers. 
Using ordinary bottle tops instead of child resistant 
containers 
Using compliance aids, such as dose reminder for tablets 
and devices to help with administration of inhaler, eye 
drops, etc. 
Daily dose reminder and monitored dose systems. 
 
Many methods were used to measure elderly patient’s compliance in previous 
studies for example patient self-reporting to indicate how the patient felt about having 
taken his/her medication during the previous month and using the community pharmacy 
computer system which illustrates the date of refill, dosage and number of tablets issued  
(Corlett, 1996, Krigsman et al., 2007). 
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2.2.4. Elderly patients and Medication review 
 
The NSF for older people recommends a medication review to reduce PCIs such 
as exclude unnecessary medications, ineffective drugs, inappropriate choice or dosing 
and non-compliance. Medication review should include all medications used by patients 
both over the counter (OTC) and prescribed (Krska et al., 2001, Lenaghan et al., 2007). 
The reasons most found for medication review were patient taking five or more 
medications (polypharmacy), to assess or improve patient compliance and to screen for 
any potential drug interaction (Penrose et al., 2004).  
In the UK, more than 80% of drugs prescribed by GPs are repeated prescriptions. 
However, they are prescribed without a consultation between the doctor and the patient. 
Repeat prescribing is poorly managed in the UK. Therefore, in 1994, the Audit 
Commission recommended that the review of long-term management might be 
inadequate (Zermansky et al., 2001). 
Pharmacists are experts in medicines and are authorised to conduct medication 
review. Several previous studies revealed that pharmacists in the community can 
effectively conduct a medication review through their clinical knowledge and expertise. 
A randomised control studies concluded that encouraging rational prescribing in 
collaboration with GPs would be more efficient (Lowe et al., 2000, Zermansky et al., 
2001).  
A trial by Zermansky et al., (2001) found that 72% of repeat prescriptions 
sampled in 50 practices had not been reviewed in the past 15 months. They concluded 
that this is potentially both wasteful and dangerous (see Figure 7 for Zermansky et al 
(2007) study). Therefore, the Royal College of Physicians and NSF for older people 
emphasised the need for regular review of treatment for elderly patients.  
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As the workload of GPs is increasing, it has been proposed that pharmacists as 
expert in drugs therapy can have crucial role in medication review for elderly patients. 
Medication review was essential part of the NSF for older people (NHS-NSF, 2001). 
 
 
Figure 7 Continuous process diagram of medications review by pharmacist 
Source: Adapted from Zermansky et al., (2001) 
Stage 1:  
Data gathering 
Stage 2: 
Evaluation 
Stage 3: 
Implementation 
Major change  Minor change  No change 
Clinical examination necessary   Discuss with 
Gp. 
Refer to Gp. Pharmacist implements change and 
document this change 
Negotiate medicine change with patient or career 
Set review data 
Review current medical problems and drugs  
A)  Consider continuing of drugs need. 
B)  Identify alternative treatment of recognized disease. 
C)  Identify any side effects 
D)  Identify any drug interaction and contraindications 
C)   Consider drug costs 
 
Patient interview to: 
A) To confirm drugs information details with patient. 
B) To confirm indications still valid.  
C)  Assess adherence of patient. 
D)  Identify any new drug related problems. 
 
Record current drugs and active medical problems 
A)  Identify drugs taken.( Medication  History). 
B)  Identify all drugs indications (rationalise of drugs taken). 
Yes  
No 
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2.3. Pharmaceutical care issues 
The recognition, avoidance and solving of PCIs are the core process of PC and 
any care activity to improve medicines use. Difficulties in detecting and describing PC 
have been internationally discussed (Krska et al., 2001). There are several drug-related 
problems categorisation systems which can be found in the literature; however, it is not 
easy to determine a comprehensive, validated instrument for the classifications 
(AbuRuz et al., 2006).  
Van Mil et al., (2004) reviewed the classifications of PCIs reported in the 
literature through searching on Medline (through Pub Med). The search was performed 
with the terms pharmaceutical care issues (PCIs), pharmacist interventions or medicine 
management therapy. Their study mentions that identifying a suitable classification is 
difficult due to different terminologies used by different researchers and institutions and 
the fact that any classification is often published only when it is used in a study.  
The optimal classification in practice should be based on clear definitions, 
published validation and the ease of use for researchers. Van Mil et al., (2004) also 
specified five major criteria for a PCI classification to be valid and reliable: 
• Clear definition for each PCI. 
• Published validation. 
• Usable in practice (used in a published study). 
• Open structure to include new problems. 
• Focus on a drug use process and outcome. 
  33 
2.3.1. Classification of Pharmaceutical care issues (PCI) in this study 
 
In preparation for the study, a literature review was initially conducted in order 
to establish and understand the different types of classification of PCIs used in previous 
studies. In a study by Lenaghan et al., (2007), only four types of PCIs were used: 
unnecessary drug therapy, ineffective therapy, inappropriate dosage schedule and non 
compliance. In this study, however, the referral rate to GP was high, around 83%, and 
the rejection was low, 3%. 
Previously Cipolle et al., (1998) had categorised PCIs into seven types of 
problems: need to add drug for valid indication, unnecessary drug used, wrong drug 
used, low dose, adverse drug reaction, high dose and finally compliance; these 
categories can be broken into further possible classes (Appendix B). Patients had a 
medical condition resulting from one of the seven categories. Therefore, all pharmacists 
providing PC must be able to identify, solve and prevent of each seven types of drug- 
related problem. Each requires intervention, care and monitoring to ensure that 
problems are resolved or prevented. 
In summary, PCIs can be easily resolved if the exact causes are known and 
understood. AbuRuz et al., (2006) and Cippole et al., (1998) reported that it is necessary 
to prevent and solve any drug therapy problems and to feel confident to detect the 
causes of that problem. The Tables 3 and 4 summarise PCIs which were used in 
previous relevant studies. 
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Table 3 Summary of Pharmaceutical care issues classification in previous studies 
 
 
Wermeille et al., (2004) 
 
 
Krska et al., (2001) 
 
Sellors et al., (2003) 
• Additional drug 
required 
• Unnecessary drug 
• Wrong drug 
• Dosage too low 
• Side effect 
• Dosage too high 
• Compliance problem 
• Confirmation of 
diagnosis 
• Absence of required 
clinical data 
• Assessment of drug 
elimination 
• Adverse drug reaction 
• Monitoring issues 
• Potential ineffective 
therapy 
• Education required 
• Inappropriate dosage 
regimen 
• Potential / actual 
compliance 
• Untreated indication 
• Drug used with no 
indication 
• Repeat prescription no 
longer required 
• Inappropriate duration 
of therapy 
• Patient not receiving 
required drug. 
• Patient is not taking 
appropriate drug. 
• Patient not taking  
drug appropriately 
• Patient is taking 
drug for which he or 
she has no 
indication 
• Patient is having  
adverse drug 
reaction 
• Patient is taking too 
much drug. 
• Patient experiencing 
drug interaction. 
 
 
 
Table 4 Summary of pharmaceutical care issues classification in previous studies 
(Cont ;) 
 
 
(De Smet and Dautzenberg, 2004) 
  
 
(Paulino et al., 2004) 
 
 
 
(AbuRuz et al., 2006) 
• Appropriateness of medication 
        dosage regimens. 
• Duration of treatment 
Medications. 
• Contraindications and 
precautions 
• Drug interactions 
• Over treatment: 
• Duplication of drugs 
• Duplication of adverse effects 
• Under treatment 
• Overuse of medication 
• Under use of medication 
• Appropriateness of medication 
• Dosage regimens 
• Uncertainty and lack of 
Knowledge of the aim and 
function of drug. 
• Overuse of drug. 
• Under use of drug 
• Drug Duplication 
• Drug –drug interaction. 
• Fail of therapy. 
• Adverse effects. 
• Swallowing difficulty. 
• Opening medication 
container difficulty 
• Incorrect use of 
administrative devise. 
• Prescribing error 
• Drug for wrong indication 
• Contraindication. 
• Others 
• Indication 
• Knowledge 
• Adherence 
• Safety 
• Effectiveness 
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2.3.2. Intervention types classification 
 
Secondly, a pre-study literature review was done to review the types of 
interventions which were used in previous studies. Hawksworth et al., (1999) classified 
the interventions in her study into: change drug, change drug use frequency , change 
drug formulation, counselling about the drug and therapeutic drug monitoring (TDM).  
In a study by Wermeille et al., (2004) they divided the intervention into two 
types, clinical intervention and non-clinical intervention and they also sub-divided the 
clinical intervention into two types according to sufficient information available which 
allowed the expert to review and classify the intervention and if there were not 
sufficient data, they excluded the intervention from the panel. They also, re-categorised 
pharmacist interventions into patient education, drug therapy related as additional drug 
required, unnecessary drug, wrong drug, dosage too low, side effect, dosage too high 
and compliance problems.  
Another classification by Needham et al., (2002) divided the interventions into 
four categories: clinical pharmacist support, teamwork or communication, medication 
supply-related and others issues. Sub-categorisations of interventions have been 
suggested which include: improving biochemical mechanisms of medication (e.g. 
avoiding benzodiazepine use amongst the elderly to prevent falls), psychosocial 
mechanisms (e.g. creating knowledge and competence and counselling) and lastly 
organisational components (e.g. inter-professional communication between pharmacist 
and doctor) (Needham et al., 2002).  
A more recent classification by AbuRuz et al., (2006) study used a variety of 
interventions types to contain almost all the types of interventions which can be 
provided by pharmacists which include patient counselling, refer to the other health care 
provider, change dose, stop drug, start new drug, change dosage regimen, monitor side 
effects, monitor vital signs, provide written information, change dosage regimen, speak 
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to family member, no intervention, monitor previous intervention outcomes, no problem 
exists and others. 
Different intervention classifications which were used by other previous trials are 
summarized in Tables 5 and 6. 
Table 5 Intervention types categories in previous studies 
 
 
 
Table 6 Intervention types categories in previous studies (Cont ;) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hawksworth et al., (1999) Bogden et al., (1998) 
 
 Missing drug  (from last PMR) 
 Drug not required (not prescribed in last 
prescription) 
 Discuss formulation of drug. 
 Change drug interval 
 Alter formulation 
 Enquiry about dose 
 Enquiry about dosage interval 
 Monitoring of plasma parameter to check 
efficacy and safety of drug regimen 
 Discuss with prescriber complete drug review 
of patient’s therapy 
 
 Lab monitoring 
 Increase medication dose 
 Discontinue medication 
 Reduce medication dose 
 Recommendation to renew medications 
 Switch to less expensive drug 
 Switch to less expensive formulation 
 Switch to other medication felt to be more 
effective 
 Others 
Paulino et al., (2004) 
 
• No interventions 
• Patient counselling. 
• Practical instruction and training 
• Prescriber refers to other health care 
provider. 
• Prescriber informed only. 
• Prescriber asked for information or 
intervention. 
• Interventions proposed by pharmacy, 
disapproved by prescriber or other 
physician. 
• Switch to other strength 
• Switch to other dose 
• Switch to other dosage form 
• Switch to other medication 
• Stopped unwanted medications 
• Referral to colleague 
Sorensen et al., (2004) 
 
• Monitoring – laboratory 
• Change drug – substitute one drug for 
another 
• Resolve non-concordance between 
patient-reported and GP-recorded drug 
regimen investigation of potential ADR 
• Provision of patient (or carer) education 
or information 
• Cease drug or trial withdrawal to 
confirm need for treatment 
• Change dose, dosage interval or 
frequency 
• Add drug 
• No recommendation made 
• Monitoring observation and non-lab 
monitoring 
• Change administration time. 
• Change route or dose form 
• Rationalise medications held in home 
• Non-drug therapy suggested 
• Other intervention to improve patient 
management 
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2.3.3. Interventions rating by clinical panel in previous studies 
 
     The third part of our pre-study literature search was to investigate the previous 
studies categorising pharmaceutical interventions specifically by use of a clinical panel. 
The classification of the intervention is a complicated process to find a reliable and 
valid classification. In the study by Needham et al., (2002), they developed a new 
classification which includes interventions likely to improve symptom control, likely to 
prevent deterioration, likely to improve compliance, unnecessary or inappropriate, 
insufficient information available to allow categorisation, intervention is important but 
effected no change and intervention was harmful for patient.  
In the study by Sorensen et al., (2004) the interventions were classified in  three 
groups. The first type is " positive intervention" , which consist of action taken leading 
to improvement in symptoms, function or disease; action taken on drug used with no 
recorded negative or positive clinical outcomes; action taken but reports of no change in 
symptoms, function, disease or drug use; and finally information provided to the patient 
to prevent possible dangers. The second type is natural intervention when outcome is 
not mentioned, action unclear, monitoring initiated but no results/effects reported or 
specified and when monitoring results show normal range. The third group is negative, 
when intervention caused development of side-effects/worsening of symptoms, function 
or disease; previous treatment re-started; drug change trialled but re-started; without an 
explanation.  
Paulino et al., (2004) used a trial clinical panel who categorised the interventions 
into interventions related to the prescriber as referral, information request, interventions 
were implemented by the prescriber or other health care provider , and intervention 
related to providing information for prescriber. Another interventions classification by 
AbuRuz, et al., (2006) suggested a reasonable intervention classification, as in Table 7. 
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Table 7 Clinical intervention categorisation by AbuRuz et al., (2006) study 
 
I No intervention 
 
Pharmacist detects PCI with no action or recommendation. 
II Patient level Counselling, education, provide written information, and speak to 
family member and other. 
 
III Drug level Change drug, stop drug, start new drug, change dosage regimen, 
change instructions and others. 
 
IV Monitoring 
 
Side effect, vital signs, lab tests and other. 
V Refer 
 
Refer to health care providers 
VI Other 
 
 
 
VII No problem exists 
 
2.3.4. Outcome measures in previous studies 
 
 The final part of the pre-study literature review was done for outcome measures 
used in different previous studies. The primary outcome measure in the original 
RESPECT study is MAI (medication appropriateness index), Secondary measures are 
knowledge, compliance and concordance of the patient and the economic measure used 
is cost of treatment for NHS or patient (Wong et al., 2004). 
In Hawksworth et al., (1999) type and nature of each intervention, the BNF category 
of the drug involved and time taken were main outcome measures, with total non-
elective hospital admissions within 6 months as the primary outcome measure and 
secondary outcomes are number of deaths, care home admissions and quality of life. 
 The study by Wermeille et al., (2004) used four different types of outcome 
measures  which  included (1) biological outcome measures ( HbA1c (glycosylated 
haemoglobin)), blood pressure (BP), lipid profile (total cholesterol, HDL-cholesterol, 
LDL-cholesterol, triglycerides), (2) Medication compliance by using the community 
pharmacy PMR system: date of refill, dosage and number of tablets registered at the 
pharmacy, (3) patient knowledge, and (4) addition or increase in dose of oral 
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hypoglycaemic, lipid lowering, antihypertensive and aspirin medicines. This was done 
by using the community pharmacy PMR system.  
Bogden et al., (1997) used absolute change in total cholesterol levels from baseline 
values and the percentage of patients who achieved the National Cholesterol Education 
Programme (NCEP) goal after 6months of community pharmacist interventions as 
outcome measures for his trial. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
CHAPTER 3 
ANALYSIS AND EVALUATION OF COMMUNITY 
PHARMACIST INTERVENTIONS IN THE 
RESPECT STUDY 
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3.1. Introduction  
 It is clearly recognised that as people get older, their use of medication tends to 
increase. In England, 21% of the population is over 60 years old and the rate of 
prescribing appears to be increasing all the time (Lenaghan et al., 2007). In the UK, data 
currently collected on all prescriptions dispensed show that older patients received 35-
40% of all drugs prescribed. Prescriptions rates are increasing for a number of reasons, 
including a rapidly growing older population, new advances in therapeutics, moves to 
treat older people more effectively and the rise in patient expectations (Thomson and 
Crome, 2002). 
Drug-related problems, particularly side effects, poor compliance with therapy 
and inappropriate drug selection are presenting in 12-14% of patients over 65% 
admitted to hospital in Scotland (Krska et al., 2001). In the USA, studies of elderly 
patients have estimated that 6–28% of hospital admissions or readmissions are 
attributable to these unintended problems. Inappropriate prescribing has been defined in 
4–53% in community-dwelling seniors which associated with increased risks of hospital 
admission (Sellors et al., 2003). 
Community pharmacist numbers in the UK have evolved and the number of 
community pharmacies has also grown. Services provided by those pharmacies include 
not only dispensing medicines but have extended to include health promotion, screening 
of disease in those with risk factors and, lately, disease management. Nowadays, the 
practice in community pharmacy has changed from a dispensing-based profession, to a 
direct care profession with the introduction of medicine management and 
pharmaceutical care. Moreover, the pharmacist has now developed new responsibilities 
such as supplementary and independent prescribing (Sellors et al., 2003). 
As older people receive around 56% of the prescriptions dispensed, The 
National Service Framework (NSF) for the elderly planned that pharmacists should play 
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a key role to reduce medicine-related problems they encountered (Lenaghan et al., 
2007). In the study published in 1999, Hawksworth and Chrystyn found Community 
pharmacists were already extending their roles gradually and were able to provide such 
care. At that time, payment was focused on volume dispensing rather than the quality of 
pharmaceutical services to the patient. Nevertheless, the dispensing process included a 
check on the efficacy and safety of each medication and in some circumstances this 
could not be clarified without discussion with the prescriber (Hawksworth et al., 1999). 
In order to further investigate the role of the community pharmacist in shared 
prescribing for elderly patients, Wong et al., (2004) described the protocol for a 
randomised multi-centre control trial of a pharmaceutical care study for elderly patients. 
In the RESPECT study, a total of 67 community pharmacies were recruited along with 
24 general practices and pharmaceutical care plans (PCPs) were drawn up for 760 
patients in East and North Yorkshire.  
The Medicines Appropriateness Index (MAI) was the primary measure. 
Secondary measures included patient knowledge, adherence, adverse events, patient- 
assessed health outcomes and treatment cost. The RESPECT study then evaluated the 
possibility and the impact of the community pharmacist input as a member of the 
multidisciplinary team caring for elderly patients. It also investigated the pharmacist 
roles in the providing of advice on medication for health care providers. In addition, the 
study also looked at the patient agreement, community pharmacist’s interest and self-
confidence, as well as physician’s collaboration and implementation of therapy 
recommendations made by pharmacists. The study further enabled the exploration of the 
community pharmacist as a health professional, easily accessible in the community, in 
supporting patient understanding of their medicines and collaborating with physicians to 
optimise the pharmacological management provided to elderly people. 
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3.2. Aims and objectives 
Our study is a retrospective study which follows on from the RESPECT study, with the 
following aims and objectives. 
This study has the following three aims: 
1. To categorise community pharmacist interventions from the RESPECT study. 
      2. To study whether the community pharmacist interventions in the RESPECT study     
produced outcomes which were effective in improving the health care of the 
elderly. 
       3. To calculate the proportion at which GPs implemented the recommendation           
made by community pharmacists in the RESPECT study. 
The aims of our study were to be achieved through the following objectives:- 
i) To categorise and investigate the number, type and nature of pharmaceutical 
     Care issues identified by the community pharmacists. 
ii) To categorise and investigate the number, type, and nature of the documented 
interventions made by the community pharmacists in the RESPECT study. 
iii) To evaluate the outcome of pharmacists’ interventions in the RESPECT study. 
iv) To investigate the implementation of the pharmacist interventions by GPs in 
the RESPECT study. 
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3.3. Method 
3.3.1. Study design 
 
This study is a retrospective trial to investigate the impact of community 
pharmacists' provision of PC to elderly patients, and a schematic design of the study is 
presented in Figure 8. 
3.3.2. Pharmaceutical care plans (PCPs) 
 
Initially, pharmaceutical care plans were copied for 398 patients from RESPECT 
data compiled by the "Lucien Research Resource Centre" (LRRC) at the University of 
York.  
Secondly, all patient data were organised into folders according to patient 
number for easy access to any information for any patient. Subsequently, and due to the 
large number of data which needed to be entered, it was decided to use "Microsoft 
Access" which allowed easy access to the patient information’s and also it helps in data 
analysis. After that, a form was designed for data which needed to be compiled and 
analysed during this period (Appendix F). 
A literature review was completed for clinical studies relevant to the study 
which explored different types of classification systems of interventions and 
pharmaceutical care issue (PCIs). This review was then used to choose a valid and 
reliable classification to investigate most of the PCIs and community pharmacist 
interventions in the study. Descriptions of PCIs are described in Appendix D. 
In our study, it was agreed to use the PCI classification mentioned by Wong et 
al., (2004) which includes: fail to receive drug, untreated condition, improper drug 
selection, unwanted medication, drug used with no valid indication, sub-therapeutic 
dose, high dose, adverse reaction, drug interaction and ,finally, others (10 categories). 
However, because of the huge number of PCIs (n=2879) in this trial, the PCIs 
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classification was extended to include follow-up (Monitoring required), efficacy of 
medications, cost effectiveness, inability to self-medicate, poor knowledge, compliance, 
prescriber problem, social problem, assess patient problem and, finally, others 
(Appendix C). 
3.3.3. Pharmaceutical interventions 
 
Regarding intervention types, the research study team was granted the use of the 
valid and reliable classification developed by Hawksworth et al., (1999). However, once 
again, because of the large number and nature of interventions in this study, it was 
agreed to modify this classification and by adding new categories of interventions (1) 
not sufficient data there were subsequently excluded from the data classified by the 
clinical panel, (2) no interventions, (3) refers patient to the other health care provider 
and (4) change time of administration (Appendix C). The Comparisons between 
intervention types used in this study and by Hawksworth et al., (1999) are listed in 
Table 8. Descriptions of intervention categories are described in appendix E. 
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Table 8 Comparison between intervention types classifications used in this study and by 
Hawksworth et al., (1999) 
 
 Interventions types used in this study Interventions types by Hawksworth et al., (1999) 
1 Monitoring Recommend monitoring 
2 Counselling Discuss drug information 
3 Assess indication Included under review medications category 
4 Review  medications Recommend medication review 
5 Switch to other medication Change drug 
6 Change dose Change dose 
7 Change duration Change duration 
8 Change frequency Change dosage  interval 
9 Discontinue unwanted medication Unrequited drugs 
10 Add new medication Change drug 
11 Change medication formulation Change medication formulation 
12 Change time of administration  Not available 
13 Contact health care provider Not available 
14 Others Others 
15 No interventions Not available 
16 Data not sufficient to classify the intervention Not available 
 
 Then, all data were entered in the Microsoft Access designed form (Appendix F) 
and, simultaneously, all PCI and interventions were clinically reviewed by the 
researcher using different drug references such as Drug Information Handbook 
(D.I.Handbook, 2004) , British National Formulary (BNF, 2004) to review and evaluate 
the therapeutic information documented in the pharmaceutical care plans (PCPs). When 
all data entry was finished, data were reviewed to ensure correct data entry and to delete 
any duplication of data (this took around 3 months). 
Subsequently, an independent clinical panel assessed each community 
pharmacist’s interventions to measure their importance according to the study by 
Hawksworth et al., (1999)  which categorised them as follows: 
• Improved efficacy of the patient therapeutic management. 
• Prevented harm to the patient. 
• Prevented a hospital admission. 
It had been decided to add a new category to the classification of interventions, 
"intervention for information only" for non-clinical issues. Also, after discussion with a 
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hospital clinical pharmacist in the clinical panel, it was suggested to add “intervention 
could be detrimental to the patient” and finally, interventions which had “insufficient 
information to classify”. 
Scores from 1-10 were given for each intervention according to the description 
of each score in table 9. For the category of " intervention for information only"  which 
the panel had agreed to classify only as " Yes"  or " No,"  in the case of " No"  the panel 
did not agree that the intervention was for information only and so reclassified and 
scored it into another category. If it was “Yes”, the panel agreed with the researcher 
classification for this intervention (Figure 9). 
Regarding " interventions for prevented hospital admission" , the clinical panel 
agreed that the two categories " intervention prevented harm to patient"  and " 
intervention improved efficacy of therapy management"  with scores of seven and over 
could be considered for possible prevented hospital admission which applied ,for 
example, to medication which could cause confusion, fatigue, dizziness and 
subsequently, falling.  
Finally, data analysis was done by using Microsoft Access, Microsoft Excel and SPSS 
version 15 to answer the following research questions: 
• What are the frequency and nature of PCIs? 
• What are the frequency and nature of interventions? 
• What is the percentage of implemented and non implemented recommendations? 
• What are the outcomes of pharmacist interventions in the RESPECT study? 
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Table 9 Descriptions of each score by study clinical panel 
 
3.3.4. Outcome measures 
 
Outcome measures used in the study were as follows: 
• Number, type and nature of PCIs identified. 
• Number, type and classification of potential interventions. 
• Percentage of implementation of pharmacist recommendations by GPs. 
• Outcomes of pharmacist intervention in RESPECT by using clinical panel. 
 
 
Score 
 
 Descriptions of each score by study clinical panel. 
 
Score 1 Could have prevented harm, but very weak support 
 
 
Score 2 
 
Can see point but only minor or non-specific. These interventions would be expected to 
be made by pharmacist as good practice. 
 
 
Score 3 
 
General monitoring and general counselling. Definite monitoring of side effects and 
biochemical monitoring, therapeutic drug monitoring (TDM) and patient progress. 
 
 
Score 4 
 
More specific monitoring and more specific counselling or more specific information 
about patient or drug 
 
Score 5 
 
Panel need external judgement about decision to make either high or low. 
 
 
Score 6 
 
Good agreement on a general good intervention such as switch Co-codamol and 
paracetamol. These interventions may prevent patient discomfort or an unnecessary side 
effect, such as change the dose PPI to maintenance dose according to current guidance. 
Subsequent possible cost saving 
 
 
Score 7 
 
More specific interventions but with more complexity. More information 
Provided by the pharmacist to determine a decision 
 
 
Score 8 
 
Very good interventions not seen as commonly. May prevent possibly more significant 
problems 
 
 
Score 9 
 
Very clearly supported, taking into account specific patient detail and need. Prevented 
potential significant events. 
 
 
Score 10 
 
Intervention was excellent 100% confidence of panel in decision. 
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Figure 8 Our Study design 
• Each intervention  presented to clinical panel to be re-
classified and scored into categorisation used by 
Hawksworth et al., (1999) 
Time scale 
4-months (re-
classification and 
scoring) 
 
• Establishment approval of classification of PCIs and 
intervention types which then approved by study 
supervisors. 
• Designing of data collection form on Microsoft Access with 
new classification. 
 
 
 
 
 
• PCPs collected for 398 patients from LRRC and organised 
infolders subsequently according to patient identification. 
 
  
2 -months 
(Data collection) 
4-months  
(Data entry in 
Microsoft access) 
2-months  
(Data classification) 
 
• All 2879 PCI’s and interventions entered into Access 
database. 
 
• Editing for all  documented clinical information by using 
suitable references, for example BNF and clinical drug data 
 
• Review all information in Microsoft Access with patient 
data in patient files to ensure correct information. 
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Classification as intervention 
“prevented hospital admission “ 
 
Scored seven (7) and over for the two categories  
• Improved efficacy of therapy. 
• Prevented harm to patient. 
 
 
 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
 
These interventions will be scored as 
No Yes 
Yes No 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
 
 
 
 
 
 
Figure 9 Clinical panel roles in this study 
 
1. Detrimental to management of the patient. 
2. Improved efficacy of therapeutic management. 
3. Prevented harm to patient. 
4. Information only 
 
 
All interventions presented for clinical panel team to classify  
Interventions’ for 
information (no 
clinical issue) 
will test into 
 
Pharmacist intervention with sufficient information helps to classify and score  
Excluded by clinical 
panel  
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3.4. Results 
The pharmaceutical care plans (PCPs) for 398 patients were selected according 
to specific criteria’s to categorise, evaluate and analyse community pharmacists’ 
interventions made by the pharmacist during the RESPECT study and to determine the 
percentage of the number of implementations of the pharmacist recommendations made 
by GPs.  
3.4.1. Data analysis 
 
Data were entered in a program specially designed for this study by the 
researcher using Microsoft Access (Appendix F). Data were then analysed using the 
statistical software package, SPSS 15 to determine the frequencies, correlations, 
difference and other statistical parameters for different variables. Microsoft Excel 2003 
was also used to draw different graphs and to determine the correlation between the 
different variables by using the pivot table and pivot graph. 
3.4.2. Patient characteristics 
 
          A total of 398 patients were chosen to be eligible for this study for they were all 
registered with the GP EMIS (Environmental Management Information system) as the 
pharmacist could download what prescribed medications the patient was on. 
Moreover, the patient should have the first and the last pharmaceutical care plans 
available in his file (i.e. month1 and month 12) to enable the pharmacist to find 
information. The average of patient’s ages was 81 and the standard deviation of ages 
is 3.74. In this study most of the participants were female 57 %( n=226) while males 
were only 43 % (n=172). 52 patients of 398 were excluded for several reasons: 1) 
Their files were missing from the record, 2) No PCI or intervention documented, 3) 
No medical therapy problem during the study period, and finally, 4) Lack of 
information in PCPs. This leaves 346 patients to be studied. 
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3.4.3. Pharmaceutical care issues (PCIs) 
 
From these 346 patients identified with PCIs, a total of 2879 Pharmaceutical 
care issues were identified by the community pharmacists with a mean (SD) 8.2 (7.2). 
The pharmaceutical care issues in the RESPECT study were classified by the researcher 
into 20 different categories. The total number for pharmaceutical care plans for all 
patients in our study is 3056 with a mean (SD) 8.85 (3.29) (appendix AH). 
We had been using the classification mentioned by Wong et al., (2004) which 
includes: failure to receive drug, untreated condition, improper drug selection, unwanted 
medication, drug used with no valid indication, sub-therapeutic dose, high dose, adverse 
reaction, drug interaction, and others. However, as discussed because of the huge 
numbers and the different types, we extended our PCIs classification to include follow-
up, efficacy of medications, cost effectiveness, inability to self-medicate, poor 
knowledge, compliance issue, prescriber problem, social problem, assess patient 
problem and finally others (Appendix C). 
All the data from each PCP was collected by the researcher in the Microsoft 
Access program which was used to enter and classify the PCIs. The results were 
presented to a clinical panel in an Access form (see appendix F) based on information 
obtained from Pharmaceutical care plans (PCPs), SPSS drugs list and patients' diagnosis 
list provided by the RESPECT team. 
Figure 10 and Appendix G shows the percentage of the most common types of 
PCIs determined by community pharmacists in the RESPECT study. 
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Figure 10 Percentage of common PCIs identified by community pharmacists 
 
The most frequent type of pharmaceutical care issues (PCIs) was related to drug 
efficacy (18%), which includes drug therapy not effective to treat the patient’s medical 
condition or any new medication initiated which needs monitoring. This was followed 
by adverse drug reactions, 17%. Next to that, an untreated condition was 12%. 
In the RESPECT study, pharmacists provided follow-up services (monitoring 
required) for elderly patients which included following up patient problems with other 
health care professionals, such as checking laboratory results, performing blood 
pressure tests, monitoring patient compliance, saving patient prescription issue, 
checking patient appointments with hospital and surgery. The frequency of this category 
was 10%. 
Recommendation by pharmacists to assess indication problems to confirm a 
diagnosis and to rationalize medications used by GPs was an important recommendation 
by pharmacists and the percentage of this category was 9%. 
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 One of major roles of pharmacists in providing PC for elderly in the RESPECT 
study was to encourage patient compliance. Inappropriate adherence (compliance 
issues) to medication was the sixth highest category at 9%. The high percentage of this 
category is due to multiple drug therapy of those patients.  
       In addition, a further category of "unwanted medication" was evident at 6% 
when the patient received a drug for an invalid indication or it was contraindicated. Poor 
knowledge category when the patient was not instructed or does not understand 
important issues regarding medication, disease, life style and non-pharmacological 
therapy recommendations was also recorded at 4%. 
 PCIs due to poor communication between patient and prescriber or health care 
professionals (prescriber problem) such as not enough supply of medication to cover the 
course of treatment, patient appointment cancelled by physician, waiting a long time for 
an appointment and the availability of medication were also detected by community 
pharmacists in the RESPECT study in the case of 2% of PCIs. 
 One of the important PCIs was inappropriate dosage regimen which includes 
wrong dose (high dose 2% and sub-therapeutic dose 2%) and inappropriate frequency or 
duration of therapy regimen. The patient may also have an inappropriate dose regimen 
because of inappropriate timing of administration. 2% of PCIs were due to actual or 
potential drug–drug interaction when the patient was receiving two drugs well known to 
cause frequent medical problems or symptoms due to their interaction. 
The rest of the PCIs were low in frequency such as therapeutic drug monitoring 
(TDM) (1.39 %) which is when the patient using drugs with a narrow therapeutic index 
such as digoxin and theophylline and cost effectiveness (0.79%), which is when the 
patient is using high cost drugs while they are available as an alternative at lower price 
with the same efficacy and safety profile. Fail to receive drug was 0.55%; this when the 
patient has a medical condition resulting from his/ her not receiving it. Improper drug 
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selection was 0.55% which was when the patient has a medical condition through taking 
the wrong drug such as one not effective for it, or the patient has an allergy for that 
medication. Next to that, were PCIs related to social a problem (0.13%) which was that 
when the patient has PCIs due to social causes, for instance loss of partner, which may 
negatively effect patient compliance and subsequently efficacy of management. Finally, 
the problem which often occurs in elderly people is that related to inability of the patient 
to self-medicate, due to frailty and dexterity. 
 Figures 11 and Figure 12 , Appendix H, Appendix I and Appendix AE show that 
community pharmacists take part in the RESPECT study started effectively within the 
first few months to determine PCIs, their frequency and the interventions declined 
dramatically over six months to reaching the lowest count at month 12. 
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Figure 11 Frequencies of pharmaceutical care issues (PCIs) identified by community 
pharmacists and interventions in each month. 
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Figure 12 Frequencies of pharmaceutical care issues identified by community 
pharmacists in different study intervals (T1= 1-3 month, T2- =3-6 months, T3 =6-
9months, T4 =9-12 months). 
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3.4.4. Pharmacist interventions 
 
           In our study, the total number of actual interventions by community pharmacists 
during the study period, after excluding no intervention category, was 2518 over a 12 
month period. The nature and frequency of the interventions were categorised into 
several types as shown in table 10 and figure 13. 
 
Table 10 Classification, frequency and percentage of interventions in RESPECT 
study 
 
Intervention types Frequency Percentage 
Monitoring 927 32% 
Counselling 288 10% 
Change dose 251 9% 
Add new medication 202 7% 
Contact health care provider 189 7% 
Switch to other medication 152 5% 
Discontinued unwanted medications 130 5% 
Review medications 113 4% 
Solve supply issue 63 2% 
Assess indication 56 2% 
Change frequency 51 2% 
Others 48 2% 
Change medication formula 32 1% 
Change time of administration 15 1% 
Change duration 1 0% 
No intervention 361 13% 
Total 2879 100% 
 
 
 
 
    
        
 
 
 
It is crucial note to that in Table 10 clarifies that in fact the total number of pharmaceutical 
care issues (PCIs) was 2879, made up of 2518 actual interventions and 361 no intervention. 
No intervention was later judged by the clinical panel as an intervention which could be 
detrimental to patients. 
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Figure 13 Frequency of each intervention type in RESPECT study 
          The first type of intervention is monitoring which was the greatest proportion of 
interventions, around 32 % (n=927). This was then sub-categorised by the researcher 
into further five categories (Figure 14 and Appendix J): a) Subjective monitoring, the 
most frequent 48% (n=447), which was regular checks of drug efficacy, adverse effects 
and therapy outcomes, b) Biochemical monitoring 31% (n=286), c) Therapeutic drug 
monitoring (TDM) for particular drugs with a narrow therapeutic index to optimise drug 
regimen 1% (n=5). d) Pharmacist recommendations for objective monitoring such as 
regular checks of blood pressure 17% (n=156) and e) Others 1% (n=4) which includes 
regular checks of patient compliance and follow up whether the pharmacists 
recommendation was implemented by GPs.  
 
 
 
 
 
 
Figure 14 Sub-classification and frequencies of monitoring  
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          The "no intervention" category occurring with second frequently 13% is 
discussed later. The second type of actual intervention was counselling, 10% 
( n=288) ,which was also sub-classified by the researcher into five further categories 
(Figure 15 and Appendix K):  a) educate patients about their drugs and diseases 
(counselling on drug information) 41%(n=119), b) encouraging patient compliance 
(Counselling on drug compliance) 15% (n=42), c) pharmacists also recommend 
compliance aids (counselling on use of compliance aids ) 7% (n=20), d) training in 
proper use of dugs and inhaler devices 13% (n=37) and e) others interventions such as 
counselling on life style change and alcohol and smoking cessation 25% (n=70). 
 
 
 
 
 
Figure 15 Sub-classification and frequencies of counselling 
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Table 10 and Figure 13 show there were a number of pharmacists recommendations for  
change in therapy regimen which includes : a) change the dose of drug therapy  9% 
(n=251), b) Add new therapy 7% (n=202), c) switch to other mediation 5% (n= 251), d) 
discontinue unwanted medications 5% (n=130), e) change frequency 2% (n=51), f) 
change medication formulation 1% (n=32) and g) change time of administration 1% 
(n=15), respectively. 
Another frequent type of community pharmacist interventions which was one of 
the important roles for pharmacists in the RESPECT study is the contact or referral to 
other health care provider to share patient clinical information. 
This was again sub-classified into three types 1) referral to GP, the most 
common at around 133 (70%), followed by 2) nurse 23 (12%) out of 189 
recommendations for referral  and finally 3)  other health care professionals  such as 
consultant, optician, physiotherapist,  etc. 33 (18%) (Figure 16 and Appendix L). 
GP
Nurse
Others
#
 
Figure 16  Referral sub-categorisation into 1) GPs (70%), 2) Nurse (12.1%) and 3) 
others (24%). 
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Table 10 and figure 13 show Less frequent recommendations to review 
medications use and solve supply issue 4% (n=113), 2% (n=63), respectively. Followed 
by recommendations to assess medication indication was 2% (n=56) and, finally, the 
“other” recommendations 2% (n=48). 
  A total of 361 (12.5%) out of 2879 PCIs were judged by the researcher to be " 
no intervention"  because either 1) documented by pharmacist who wrote in PCPs no 
further action needed by the pharmacist " 2) there was nothing documented about that 
intervention for PCI for the same patient, 3) the information provided was insufficient to 
classify that intervention. Table 10 also, clarifies that in fact the total number of 
pharmacy interventions was 2879, made up of 2518 actual interventions and 361 no 
interventions. 
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3.4.5. Implementation of pharmacist recommendations by GPs  
 
A key aspect of the RESPECT study was that some PCIs were excluded where 
there was no documented intervention for any PCIs on the PCP or the information 
available was insufficient to decide whether the GP accepted the community pharmacist 
recommendation. Furthermore, when a pharmacist made a particular intervention such 
as patient counselling for life-style modification (dietary and exercise advice), if it was 
not followed up and agreed by the GP, it was discounted as not applicable and excluded 
(see Appendix M). Overall, GPs accepted (715) 80.35% of the community pharmacist’s 
recommendations out of a total of 890 (100%) and declined to accept (175) 19.4%, after 
we excluded the categories above (Figure 17 and Appendix AF). The excluded 
categories are very important and are discussed in more detail later. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17 Percentage of community pharmacist interventions accepted by GPs after 
excluding categories "not sufficient information" and "not applicable". 
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It had been agreed that the main source of information about GPs’ 
implementation was the SPSS drug list provided by the RESPECT team. Also, the 
researcher used the patient PCPs for the same purpose. 
 The drug list in SPSS consists of 4 fields which include drug name, strength, 
formulation and study period, as shown in the example in Appendix N. Therefore, this 
can only help to determine the implementation of pharmacist recommendations related 
to change of therapeutic regimen , such as 1) changing the dose either by increase or 
decrease, 2) switching to other medications 3) initiating new drug therapy, 4) changing 
of medication formulation, 5) change drug use frequency and 6) discontinue Unwanted 
medication ( Table 11). 
 
Table 11 Frequency of implemented and not implemented interventions for each type of 
intervention category 
 
 
 
 
 
No Intervention types Yes No Total 
1 Add new medication 138 36 174 
2 Assess indication 14 2 16 
3 Change dose 164 52 216 
4 Change frequency 33 1 34 
5 Change medication formulation 24 6 30 
6 Change time of administration 7 0 7 
7 Counselling 12 2 14 
8 Discontinue unwanted medication 93 28 121 
9 Monitoring 78 9 87 
10 Others 6 3 9 
11 Refers to other health care provider 9 2 11 
12 Review medication 15 2 17 
13 Solve supply Issue 20 0 20 
14 Switch to other medication 102 32 134 
 Grand Total 715 175 890 
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Figure 18 Implementation and non-implementation of pharmacist’s interventions for 
each intervention category (graph of pivot table). 
 
Table 11, Figure 18 and Appendix M illustrate the frequencies of 
implementation by GPs for each type of community pharmacist intervention. It was 
found that the most frequent type implemented by GPs was the recommendation which 
changed therapeutic regimen compared to other types of pharmacist recommendation. 
  
Table 12 Percentage of implemented recommendation by GPs in therapeutic regimen 
categories 
 
NO Intervention types % of accepted recommendation  by  GPs 
1 Change medication formulation 80% 
2 Add new medication 79% 
3 Discontinue Unwanted medication 77% 
4 Switch to other medication 76% 
5 Change  dose 76% 
 
 
  65 
Table 12 and figure 19 and appendix O show the percentage of frequency of 
GPs’ implementation for each therapeutic regimen change categories as follows: 1) 
Change medication formulation 80% (n=24), 2) added new medications 79% (n=138), 3) 
discontinued unwanted medications 77% (n=93), 4) switch to other medications which 
were accepted by GP 76% (n=102) and finally 5) change dose 76% (n=164). 
 
Figure 19 Proportion of accepted and declined recommendations for particular 
interventions related to changing therapy regimen 
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Out of 2879 total number of the interventions documented, (715 were accepted 
and 175 rejected) and 361 had no intervention. So a total of 1628 had an unknown 
outcome. In order to know the outcome of these 1628 pharmacist’s interventions in the 
RESPECT study with unknown outcomes (either no information available to know if 
the pharmacist recommendation was implemented by GPs and interventions that were 
not applicable because the GP was not involved), the clinical panel re-categorization 
and scoring for these intervention was used to determine their importance as in Tables 
13 and 14. Table 14 shows potential prevented hospital admissions. 
Table 13  Further analysis of GP implementation of community pharmacist 
recommendation for the two categories "No information" and "Not applicable"  
 
 
 
Table 14 Frequency of intervention with unknown outcomes with scoring 7 or more 
(Interventions with the potential to prevent hospital admissions) 
 
Panel re-categorization Unknown  outcomes Accepted Rejected 
No 
 intervention Total 
Prevented Harm to the patient 116 118 30 0 264 
Improved efficacy of management 52 45 6 0 103 
Detrimental  to the management 2 2 2 15 21 
Information only 0 0 0 0 0 
No enough information to classify 0 0 0 0 0 
Total 170 165 38 15 388 
 
 
 
 
Panel re-categorisation 
 
Unknown  
outcome 
 
Accepted Rejected No intervention 
Panel 
frequency 
Prevented harm to the patient 760 (47%) 372 103 8 1243 
Improved efficacy of management 578 (36%) 263 49 7 897 
Detrimental to the management 14 (1%) 13 10 51 88 
Information only 214 (13%) 55 11 58 338 
Insufficient information to classify 62 (4%) 12 2 237 313 
Total 1628 (100%) 715 175 361 2879 
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3.4.6. Researcher re-categorisation of pharmacist interventions  
 
 
0
200
400
600
800
1000
1200
Prevented hospital
admission
Prevented harm to 
patient
Information Improved efficacy
of management
Detrimental to
patient
management 
Categories
Fr
eq
ue
nc
y
Figure 20  Researcher re-categorisation of percentage of community pharmacist 
interventions in RESPECT study according to study by Hawksworth et al., (1999) 
 
 
Before the clinical panel was recruited, all 2879 interventions of the community 
pharmacists in the RESPECT study were reviewed by the researcher and re-categorised 
according to the Hawksworth et al., (1999) categorisation. 
Figure 20 and Appendix P illustrate the re-categorisation which was made by the 
researcher according to Hawksworth et al. (1999) and frequency of each category . It 
reveals that around 38% (n=1081) of pharmacist interventions were classified as 
improve efficacy of management, 35% (n=1015) as prevent harm to patient 
management and 11 % (n=312) as for information only such as information about 
outcomes of management and laboratory results. Furthermore, 3% (n=84) were 
classified as interventions which could prevent hospital admissions and 3% (n=79) only 
were classified as detrimental to patient management. Finally, the insufficient 
information to classify" category was used for 308 (11%). 
Note: This classification was not considered as important to the study as the 
clinical panel work. 
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3.4.7. Panel re-categorisation of pharmacist interventions 
 
Full details of each community pharmacist intervention were retrospectively 
assessed by a clinical pharmacists’ panel (one hospital and two community clinical 
pharmacists). The clinical panel categorised the types of interventions according to the 
classification by Hawksworth et al., (1999). 
The clinical panel assessed the potential of each community pharmacist 
intervention as 1) intervention could prevent harm to the patient, 2) intervention could 
improve efficacy of patient management, 3) intervention detrimental to patient 
management, 4) interventions for information only, and finally 5) insufficient 
information to classify and this intervention excluded. The clinical panel assessed 2879 
interventions which had been initially assessed and classified by the researcher into the 
sub-headings. Of these, 338 (12%) had been judged to only provide information to the 
patient and other health care providers (no clinical intervention (Appendix Q). The 
panel did not score this category. Instead the panel only gave a "Yes"  if the panel 
agreed with the researcher opinion that it was for information only and a " No"  if the 
panel did not accept that opinions. Any interventions assessed by the clinical panel 
which did not agree with the researcher classification were moved into the appropriate 
category. 
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Figure 21 Percentage of each clinical panel reclassification A= could prevent harm to 
patient, B= could improve efficacy of patient management, C= interventions detrimental 
to the patient management, D= for information only, E= Insufficient information to 
classify and excluded. 
 
Figure 21 and Table 15 show that the independent clinical panel categorised 
43% (n= 1243) out of the 2879 community pharmacist interventions in the RESPECT 
study as " prevented harm to patient management", 31 % (n=897) " improve efficacy of 
management", 12% (n=338) " interventions for information only" and only 3% (n=88) 
of them were judged as could be detrimental to patient management. In addition 313 
interventions were excluded due to lack of information to help to classify them.  
 
Table 15 Clinical Panel re-categorisation of community pharmacist intervention in the 
RESPECT study according to Hawksworth et al., (1999) 
 
Researcher ranking Panel frequency Panel Percentage 
Prevented Hospital admission -- -- 
Prevented harm to the patient 1243 43% 
Improved efficacy of management 897 31% 
Detrimental to the management 88 3% 
Information 338 12% 
Insufficient information to classify  313 11% 
Total 2879 100% 
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Further analysis, discussed later in table 19 shows how the clinical panel at the 
last step decided which interventions could prevent a hospital admission, of which there 
were 367 by including those with a score of 7 or more for the two categories " improved 
efficacy of management"  and " prevented harm to the patient" . 
 
 
Table 16 Comparison between researcher and clinical panel  re-categorisation of  
pharmacist intervention in RESPECT study according to Hawksworth et al.,(1999).  
 
Interventions re-categorisation Researcher frequency 
Researcher 
percentage 
Panel 
frequency 
Panel 
percentage 
Prevented hospital admission 84 3% -- -- 
Prevented harm to patient 1015 35% 1243 43% 
Improved efficacy of management 1081 38% 897 31% 
Detrimental to management 79 3% 88 3% 
Information only 312 11% 338 12% 
Insufficient information to classify 308 11% 313 11% 
Total 2879 100% 2879 100% 
 
 
 
 
 
 
 
 
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
50%
Prevented
hospital
admission
Prevented harm
to patient
Improved
efficacy of
management
Detrimental to 
management
Information only Insufficient
information to
classify 
Categories
Pe
rc
en
ta
ge
 
Researcher frequency Panel percentage
Figure 22 Comparison between researcher and panel ranking for intervention 
reclassification according to Hawksworth et al.,  (1999). 
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The comparison between the researcher and the clinical panel categorisation 
revealed that there was a difference between the two classifications for different types 
of community pharmacist interventions in the RESPECT study (Table 16 and Figure 
22). It was found that the most frequent types of intervention determined by the 
researcher were those to improve efficacy 1081 (38%), followed by those to prevent 
harm to patient management 1051 (35 %). Whereas in the judgement of the clinical 
panel, it was the category prevents harm to patient management which was the most 
frequent 1243 (43%), followed by improve efficacy 897 (31%). The researcher and 
panel have almost the same judgment regarding interventions detrimental to the patient 
79 (3%) and 88 (3%), respectively, and for information only 312 (11%) and 338 (12%), 
respectively. However, in the category interventions which prevented hospital 
admission there was a big difference between researcher and panel judgements 84 and 
367, respectively (Table 16 and Table 19). 
 
Table 17 Correlation between each intervention and panel categorisation 
 
Intervention types 
Prevented 
patient 
harm 
Improved 
drug efficacy 
Detrimental to the 
patient management 
Information 
only 
Monitoring 582 245 4 47 
Counselling 92 167 4 20 
Assess indication 9 44 2 1 
Review medication 21 79 1 11 
Switch to other medication 96 43 2 9 
Change dose 117 119 5 7 
Change duration 1 0 0 0 
Change frequency 21 24 3 0 
Discontinue unwanted 
medication 98 17 9 4 
Add new medication 117 68 4 7 
Change medication 
formulation 6 20 0 6 
Change time of 
administration 3 11 0 1 
Solve supply issue 12 7 0 44 
Contact health care 
provider 47 28 2 110 
Others 13 18 1 13 
No intervention 8 7 51 58 
Total 1243 897 88 338 
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Figure 23 Correlation between pharmacist intervention types and the clinical panel re-
categorisations 
 
Table 17 and Figure 23 show the correlation between each intervention type and 
panel classification. Monitoring is the most frequent type of pharmacist intervention 
which can potentially prevent harm to the patient (47%, n=582), followed by change the 
dose and added new medication which had the same percentage (9%, n= 117), Then 
discontinue unwanted medication (8%, n=98) and switch to other medications (8%, 
n=96). 
The pharmacist’s recommendation for monitoring was also the most frequent 
intervention categorised by the panel as improve efficacy of management (27%, n=245), 
followed by "patient counselling" (19%, n=167), and then "change the dose" (13%, 
n=119). Then, review of patients medication (9%, n=79), after that was add new 
medication (8%, n=68), recommendation of community pharmacists to "assess the drug 
indication" and "switch to other drug" had almost the same frequency and percentage 
(5%, n=44) and (5%, n=43) respectively. 
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The panel classified the intervention category "no intervention" as the most 
frequent types which can be "detrimental to patient management" (n=51), followed by 
"discontinue unwanted medication" (n=9) and then " change drug dose (n=5). 
Contact (referral or discuss patient problems) with other health care providers 
was the most common type of pharmacist intervention, judged by the panel as 
interventions for information only (33%, n=110), followed by " no intervention" 
category (17%, n=58) when there was insufficient information to classify the 
intervention but it was still relevant, and finally, recommendation for monitoring was 
(14%, n=47) when there was a follow-up for the laboratory results. 
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3.4.8. Panel intervention scoring 
 
For the two categories " prevented harm"  and " improve efficacy" , each 
community pharmacist’s intervention in the RESPECT study was graded by the clinical 
panel on a 1-10 scale to emphasise the confidence of the clinical panel regarding the 
importance of these interventions (see table  9 for the definition of each score). 
Table 18 and Figure 24 show that for interventions related to prevent harm to patient 
management category out of a total of 1243, 28% were given score 3 by the panel, 21% 
were rated as score 6, about 19% were given score 4, 13% were given score 7, 8% score 
2, around 6% score 8, and finally scores 1 and 9 were given for only 2% of the 
pharmacist interventions. 
For interventions related to improved efficacy of management, from a total 897 
32% were given score 4, followed by score 6 for 26% of interventions, score 3 for 24%, 
then score 7 for 8%, score 8 for 2% and finally scores 1 and 9 for only 1%. 
 
 
Table 18 Clinical panel scoring of each community pharmacist’s intervention re-
categorisation 
 
Interventions  Score 
 
Prevented harm 
 
 
Improved efficacy 
 
Detrimental to the patient 
 
 Frequency Percentage Frequency Percentage Frequency Percentage 
Score 1 24 2% 11 1% 10 11% 
Score 2 100 8% 46 5% 14 16% 
Score 3 350 28% 218 24% 15 17% 
Score 4 241 19% 285 32% 13 15% 
Score 6 263 21% 233 26% 15 17% 
Score 7 167 13% 74 8% 10 11% 
Score 8 78 6% 22 2% 3 3% 
Score 9 19 2% 7 1% 8 9% 
Score 10 0 0 0 0 0 0 
Total 1243 100 897 100 88 100 
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Figure 24 Panel scoring of  community pharmacists  interventions in the RESPECT 
study according to Hawksworth et al.,  (1999) 
 
As mentioned earlier regarding table 16 and 19, the category prevented hospital 
admission was introduced by the clinical to include interventions with score ≥ 7 from 
both "prevented harm" and "improve efficacy" categories. Table 19 reveals that 367 
interventions were related to the two categories "prevented harm to the patient" and 
"improve efficacy of management" where there had been allocated a score by the 
clinical panel of seven or more (≥ 7) (Appendix R and S shows the interventions types 
which could have prevented hospital admission). 
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Table 19 Numbers of interventions classified by panel to have a potential to prevent 
hospital admissions 
 
 
If this is extrapolated further, Figure 25 shows estimated potential saving for the 
NHS as a result of community pharmacist interventions in the RESPECT study. This 
money saving was calculated using the format provided by the Hawksworth et al., (1999) 
study.  
 
 
 
 
 
 
 
 
 
Figure 25 Estimated money saving for NHS  if Hospital admissions were prevented by 
community pharmacists interventions  (based on format by Hawksworth et al.,(1999). 
 
 
Score ≥7Prevented harm ≥7 Improved efficacy 
Score 7 167 74 
Score 8 78 22 
Score 9 19 7 
 264 103 
Total 
367 
Average cost /night= £275 
 
Average Hospital stays=3-
7 days 
 
Estimated saving for NHS by the clinical 
panel =£504,625 
Total interventions could prevent hospital stays=367 
  77 
Score range (6-10) indicates high panel confidence in the importance of the 
interventions in question. Meanwhile, the score range (1-4) implies low panel 
confidence in the importance of the intervention. As shown in Figure 24 and table 18, 
no clinical intervention was given the maximum score of 10. However, in table 18 
around 336 (38%) of community pharmacist interventions were graded 6-9 as having a 
potential to improve efficacy. In contrast, around 560 (63%) were graded 1-4. Most of 
the pharmacist interventions in the category improved efficacy of management were 
graded by the clinical panel at score 4 (32%, n=285) which is defined as more specific 
interventions and more specific to drug, followed by score 6 (26%, n=233) which means 
interventions gets good panel agreement and cost saving is possible. Next to that was 
score 3 (24%, n=218) which is defined as general intervention such as general 
monitoring and counselling (not specific). With regard to interventions judged by the 
panel as prevented harm to the patient, most interventions scored 3 (28%, n=350), 
followed by score 6 (21%, n=263), then score 4 (19 %, n= 241), and finally score 7 
(13%, n=167) 
Regarding interventions categorised as detrimental effect to the patient 
management, these have reverse scoring. So, if the score is high (6-9) then the 
intervention is very dangerous to the patient and vice versa for lower scores (1-4). The 
interventions were distributed evenly among the whole range of scores; score 1 (11%, 
n=10), score 2 (16%, n=14), score 3 (17%, n=15) score 4 (15%, n=13) and score 6 (17%, 
n=15), score 7 (11%, n=10), score 8 (3%, n=3) and lastly score 9 (9%, n=8). 
It was agreed to give the score of 5 for community pharmacist interventions 
where the panel had a difference of opinion about their categorisation or scoring 
( positive or negative) and there was a need for an external view by a senior clinical 
pharmacist to decide in which category to place the intervention and which score it 
should be given. 
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Table 20  External senior clinical pharmacist’s judgement on re-categorisation of 
interventions scored 5 by study clinical panel 
 
 
Table 20 shows that a total of 34 of the pharmacist interventions in RESPECT 
were scored as 5. Of these, the external judge gave a score of 6 to 10 interventions 
related to category ‘improved the efficacy of management’ and score of 6 to 5 
interventions related to "prevented harm to the patient management". Score 4 was 
allocated to 5 interventions related to ‘improve efficacy of management’. One 
intervention related to prevent harm to patient management and two interventions to the 
‘detrimental to the patient management’ were given score 7. Maximum score 9 was 
given to two interventions: one related to ‘detrimental to the patient management’ and 
the other to prevented harm to the patient management. In contrast, the minimum score 
1 was given for one intervention of category ‘prevented harm to the patient 
management’. 6 interventions were excluded from scoring, 4 due to insufficient data 
provided and 2 judged as interventions for ‘information only’ and finally, score 3 was 
given for only one intervention related to ‘harm to the patient management. 
Scoring Prevented harm 
Improved 
efficacy 
Detrimental to 
the 
management 
Information 
only 
Not enough 
information Total 
Not applicable 0 0 0 2 5 7 
Score 1 1 0 0 0 0 1 
Score3 0 1 0 0 0 1 
Score 4 0 5 0 0 0 5 
Score 6 5 10 0 0 0 15 
Score 7 1 0 2 0 0 3 
Score 9 1 0 1 0 0 2 
Total 8 16 3 2 5 34 
  79 
3.4.9. Drug dispensed for our study patients  
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Figure 26 Number of drugs prescribed in each study interval, T1 after 3months of  PC, 
and T2 after 6 months and T3  after 9 months  and T4 after 12 (T5= Post-study period 
excluded due to missing data in SPSS list provided)  
 
At the end of the study a further analysis was made and it was found that the 
total number of repeated drug items prescribed in each of the five intervals of the 
RESPECT study gives the total number of items in the whole period which was 11713 
items for the whole period with the mean (SD) 35.9 (12.38) (Appendix Y). This data 
was according to the SPSS drug list provided including T5 (post study period) after 
excluding patient duplication and patients presented on the list but not included in our 
study. In order to investigate the cost effectiveness of pharmaceutical care (PC) 
provided to elderly patients in the RESPECT study, further analysis was carried out to 
calculate the reduction in the number of drugs for all participants during each of the 
study intervals. Figure 26 reveals the total number of items in repeated prescriptions for 
participants in each study intervals. The total number of medications prescribed during 
each study period is gradually increased from T1 (period after 3month) 2348, T2 (period 
after 6months) 2406 and T3 (after 9months) 2478 to reach the highest score in T4 (after 
12 months) 2591. Then, there was dramatic reduction in T5 (post study period) 1890. 
However, this does not reflect the actual reduction in medications prescribed due to 
poor documentation by community pharmacists and problems with data collection for 
this period of the study. 
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Figure 27 Percentage of drugs regularly prescribed in the RESPECT study according to 
the BNF classification 
 
All the drugs involved in the RESPECT study were classified according to the 
British National Formulary (BNF) classification. As shown in Figure 27 and Appendix 
T, medications related to cardiovascular system (C.V.S) (Category 2) were the most 
frequent involved in the RESPECT study (34.3 %), followed by central nervous systems 
(C.N.S) medications (Category 4) 18.82%. The first category in the BNF medications 
related to Gastro-intestinal systems (Category 1) were the third more frequently 
prescribed (9.91 %). Less frequently prescribed were drugs for treatment of muscle, 
skeletal and joint diseases (Category 10) (8.66 %), Nutrition and blood drugs 
(7.68 %) ,Endocrine systems diseases ( Category 6) such as diabetes and thyroid 
disorder (6.63%), and finally Respiratory drugs ( Category 3) such as asthma 
medications and antihistamine (6.58 %). Other drug categories for example eye, urinary, 
ear, nose and oropharynx medications, were the least prescribed at a minimum rate in 
the RESPECT study. 
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Figure 28   Most frequent drugs dispensed in the RESPECT study 
  
Figure 28 and Appendix U show the drugs most commonly prescribed in the 
RESPECT study according to the SPSS drug list provided. Of these, Aspirin as an anti-
platelet was the most common (3.8%, n=495), followed by Atenolol (3.16%, n=412), 
Warfarin (2.9%, n=382), Simvastatin and Aspirin E/C were almost the same frequency 
(2.8 %, n=369) and (2.8%, n=340) respectively, with Frusemide (2.61%, n=340). The 
common analgesic Paracetamol was also prescribed at a higher rate (2.5%, n=326) 
Bendrofluazide was also frequently seen in repeated prescriptions in the RESPECT 
study (2.06%, n=326) Figure 29 bar chart describes the frequency of each medication 
category in each study interval.  
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Figure 29 Number of medications in each of study intervals according to BNF 
classification, , T1 after 3months of  PC, and T2 after 6 months and T3  after 9 months  
and T4 after 12 (T5= Post-study period excluded due to missing data in SPSS list 
provided)  
 
Appendix z shows there is significant difference between the drugs prescribed in the 
four intervals T1, T2, T3 and T4 (p-value= 0.00274).  
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CHAPTER 4 
GENERAL DISCUSSION AND CONCLUSION
  84 
4.1. Discussion 
For the vast majority of people, access to community pharmacists is easier than 
to other health care providers. In the UK, one of the NHS priorities is to ensure that 
patients can get their medicine and advice easily at the time and the place they choose 
and to help patients who cannot get the best from their medicine because they are not 
using their medicine properly. This can reduce the amount of medication which is 
simply wasted (NHS, 2008). 
On 1 April 2005, the new pharmacy contract was introduced by the 
Pharmaceutical Services Negotiating Committee (PSNC), UK Health, in conjunction 
with the NHS Confederation which agreed a pharmacy new contract (Wong et al., 2004). 
Community pharmacists in the UK under the new contract were to be rewarded for the 
quality of pharmaceutical care provided rather than the amount of drugs dispensed. 
Furthermore, in the new contract, community pharmacists could be paid for extending 
their roles to include blood pressure testing, blood sugar monitoring, offering smoking 
cessation and counselling on health style change. This provided an opportunity for the 
research team in the RESPECT study to evaluate pharmaceutical care provided by 
community pharmacy for elderly people (Wong et al., 2004). 
Older people are usually suffering from chronic morbidity from multiple 
diseases. This may require co-current drug treatment (polypharmacy) which is known to 
be associated with an increased risk of drug-related problems (PCIs) such as poor 
compliance, adverse effects, drug-drug interaction and wrong dosing regimen (Corlett, 
1996). 
The RESPECT study which took place in 2004 before the introduction of the 
new pharmacy contract, demonstrates that the integration of the community pharmacist 
into the multidisciplinary team has a positive effect on elderly patients, with 
pharmacists becoming a useful partner in choosing and monitoring medication therapy. 
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It also has demonstrated the possibility and acceptability of a collaborative relationship 
between GPs and specially trained pharmacists in providing PC for elderly patients. 
In our study, 398 patients were identified according to specific criteria as all the 
patients chosen should be registered in EMIS system practices as it could then be 
possible to download what medications the patient was on. A further criteria was that 
the patient file should contain first and last pharmaceutical care plans (i.e. month1 and 
month 12).  
The distribution of gender for the patients revealed that the numbers of females 
were higher than males (57% to 43%). Of these 52 patients were excluded because their 
files did not contain the entry criteria information. The analysis of the pharmaceutical 
care plans ( PCPs) for 346 patients shows that during a period of one year, 2879  
pharmaceutical care issues were identified  by community pharmacists in the RESPECT 
study with mean (SD) of 8.85 (3.2) and an actual 2518 interventions were made by them 
as 361 had no intervention. 
Despite, the fact that we had excluded several PCPs due to insufficient data 
being documented, our study still has the highest number of PCIs 2879 compared to 
2156 (1380 in the intervention group and 950 in the control group) in the study done by 
Krska et al., (2001); furthermore , 2518 actual interventions compared to 1503 in the 
study by Hawksworth et al., (1999). This may be due to the large sample size of patients 
the pharmacists recruited and the vast resource invested in the RESPECT study 
compared to other studies. 
The characteristics of the participant pharmacies show several differences. In the 
RESPECT study, pharmacists were paid to take part in this study and 67 pharmacies 
were recruited into the trial compared to 18 unpaid pharmacies in Hawksworth et al., 
(1999). However, the number of pharmacists who participated in the RESPECT study 
was unlimited as long as they attended the required training and provided PC as 
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instructed, compared to the fourteen community pharmacists recruited to participate in 
the Krska et al., (2001) study and the 14 in the study by Hawksworth et al., (1999). 
Furthermore, the sample size of patients in the RESPECT study was large (760) 
compared to 381 patients in Krska et al., (2001). 
         In our current study, we reviewed and investigated all PCPs in the RESPECT 
study and, as in the Hawksworth study, estimated the outcome of the community 
pharmacist interventions by introducing an expert clinical panel to re-categorise and 
grade them to evaluate their importance. 
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4.1.1. Classifications of pharmaceutical care issues  
 
Most classifications of PCIs in previous studies were identified through on 
"PubMed" and "Yahoo" searches. In this study, we searched for pharmaceutical care 
issues (PCIs) and interventions classifications in Medline PubMed, Web of knowledge 
and Scholar GOOGLE by using the terms Pharmaceutical care issues classification 
(PCIs), medications adverse events classification, medication error types and 
pharmaceutical care classification. 
Although the definition is an essential element of any classification (Van Mil et 
al., 2004), most of the previous studies do not provide a clear definition of their 
classifications. Meanwhile, the classifications used in our study clearly define each PCI 
and intervention type as outlined in Appendix D and E. 
In our study, it was difficult to find suitable classifications due to the huge 
number of PCIs identified by the community pharmacists in the RESPECT study. So, it 
was decided to adopt a modified version used by Wong et al., (2004)  in the RESPECT 
study, as shown in the Appendix C. 
At the end of our study, in order to create a more useable, easy classification for 
PCIs in future studies, the researcher pharmacist subsequently created a more 
comprehensive and easier classification which includes most types of PCIs which would 
be expected in such studies. The researcher pooled the 20 categories into 13 as in 
Appendix V, in which "untreated condition" and " fail to receive drugs" were put in one 
category to become "Fail to receive drug". "Therapeutic drug monitoring" (TDM)," 
follow up" and "assess patient problem" were put into one category to become 
"monitoring required". The "inability to self medicate"  category was added to the " 
compliance issues"  category and finally we condensed the minor frequency categories " 
prescriber problem"  and  "social problem"  to become under the category "others" . 
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Another classification in a well designed study was made by AbuRuz et al., 
(2006). They pooled all the PCIs into only 7 categories (Appendix X) which are 
different from our classification. If we had been implementing this classification in our 
study, it would have resulted in the following from our results: 1) Indication 30% 
(n=851) which includes "assess patient problem" (n=271), "drug used with no valid 
indication"  (n=40), "unwanted medication"  (167), "untreated condition"  (357) and " 
improper drug selection"  (n=16) ; 2) Efficacy 23%( n=653) which includes "efficacy of 
medications"  (n=527) , "high dose"  (n=65) and "low dose"  (n=61) ; 3) Safety 23% 
( n=551) which include "adverse drug reactions" (485) and " drugs interaction" (50) and 
"fail to receive drugs"  (n=16) 4) Compliance 9% (n=257)) ; 5) Poor knowledge 4% 
( n=113) 6) Follow up (monitoring required) 12% ( n=335) which include biochemical 
testing and TDM finally 7) Miscellaneous 4% (n=118) which includes categories with 
no minor frequencies such as "cost effectiveness" , "prescriber problem"  and " social 
problem"  as compared to Figure 10 in the results. The previous classification can 
provide a clearer picture regarding the nature of PCIs in the RESPECT study compared 
to our classification (Figure 10). The issues related to drug efficacy were the most 
common PCIs in this study, followed by problems linked to safety (ADRs and drug 
interaction and monitoring).  
4.1.2. Pharmaceutical care issues (PCIs) in the RESPECT study 
 
Using the modified version of classification used by Wong et al., (2004) in the 
RESPECT study (Figure 10) the problems related to 1) Drug efficacy, 2) Side effects 
(ADRS) and 3) Untreated condition and 4) Follow up (Drugs required monitoring) were 
the most common pharmaceutical care issues in the RESPECT study. This is close to 
the finding reached by Krska et al., (2001), in which 1) Suspected adverse drug reaction, 
2) Monitoring issues and 3) Potential ineffective therapy were the most frequent PCIs. 
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Figure 10 shows that the most common reason for pharmacist intervention (PCIs) 
in the RESPECT study was problems related to drug efficacy (18%); this was when the 
drug therapy was not effective or where a new medication therapy had been recently 
initiated and there was a need to monitor its efficacy. The detecting of such problems by 
community pharmacists during the dispensing of repeat medication and the use of their 
patient medications records (PMRs) could have positive cost saving to NHS. This 
category, judged by the clinical panel to improve the efficacy of management and 
subsequently could prevent a hospital admission if an intervention was suggested, was 
scored highly by the clinical panel. Figure 10 shows that the second most common 
reason for pharmacist intervention was potential/ suspected adverse drug reaction 
(ADR) (17%) when the patient is receiving a medication with known and frequent side 
effects. This could have negative complications such as a new medical problem, 
disability, and death if the pharmacist does not detect it. The clinical panel judged that 
the detecting and the ability to resolve such interventions could prevent harm to the 
patient management and deserved a high score. 
Nowadays, adverse drug reactions (ADRs) in the elderly are an increasingly 
important problem in health care systems. The importance of this issue is not only due 
to the increased morbidity and mortality of patients but also, because of the financial 
burden associated with ADRs (Cresswell et al., 2007). 
In a study of two hospitals in England, it has been found that ADRs cost the 
NHS £466 millions annually. The risk was doubled if the patient was 65 or older. The 
increase risk of adverse reactions in elderly patients is due to a combination of: 1) 
physiological decline in renal and hepatic function, and 2) co-morbidity due to drug-
disease interaction in case of polypharmacy and chronic multiple diseases (Cresswell et 
al., 2007). 
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Adverse drug reactions are one of the major causes of hospitalisation in the UK 
(6.5%), resulting in significant use of beds in the NHS and a significant number of 
deaths (Pirmohamed et al., 2004). Most of the side effects in the elderly, such as 
gastrointestinal problems which are due to the use of NSAIDS, or fall, confusion, 
vertigo or dizziness due to using of benzodiazepine or anti-depressants such as SSRIs, 
are preventable through simple interventions by trained pharmacist to improve 
physician prescribing (Pirmohamed et al., 2004). 
 Figure 27 and 28 shows a selection of the most BNF drugs classes most 
involved in PCIs in the RESPECT study were cardiovascular drugs (CVS) for example 
antiplatlets drugs (Aspirin), antihypertensive such as beta-blocker (Atenolol), diuretics 
(Frusemide and Bendrofluazaide), anti-coagulant (Warfarin), anti-ischemic (Isosorbide 
mononitrate) and hyperlipidemia drugs (Simvastatin and Atorvastatin), followed by 
central nervous system drugs (CNS). These include for example analgesics (Co-
codamol and Co-proxamol). These classes of medications are frequently prescribed for 
the elderly as in the study by Pirmohamed et al., (2004). 
 The severity of ADRs increased with aging for example warfarin tendency to 
cause serious side effects such as haemorrhage in overdose or thrombus formation in 
low dose increased in older people. In UK, The National Patient Safety Agency (NPSA) 
was informed of 450 cases of harm due to use of anticoagulants in the UK from 1990-
2002. Furthermore, there were 120 deaths in the same period and warfarin was 
responsible for about 77% of them. As a result of the risk assessment, the agency 
released safer practice solutions for anticoagulant use (Baglin et al., 2007).  
Several studies have demonstrated that pharmacist clinical interventions during 
the dispensing process can reduce the adverse effects and clinical pharmacy services can 
reduce patient mortality due to adverse effects (Krska et al., 2001, Hawksworth et al., 
1999, Pirmohamed et al., 2004).  
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Appendix AD shows that community pharmacists in the RESPECT study made 
several types of recommendations to prevent ADRs (no 13 in vertical axis) which 
include their recommendation for monitoring symptoms of side effects( no 1 in 
horizontal axis) (subjective or observational monitoring) which was the highest, aiming 
to ensure that symptoms are drug or dose-related not disease-related or to observe the 
severity of that side effect to evaluate the benefit of using the medication outweigh the 
risk. The frequency of this category was 156 out of 485, followed by "switch to other 
medication" (n=61) and then "change the dose" if the side effects are dose-related 
(n=53), next to which was discontinue medication causing the ADRs "discontinue 
unwanted medication" (n=46). The last finding emphasises the potential benefit of 
community pharmacist interventions in the health care system and cost saving for the 
NHS. 
For the vast majority of the public, community pharmacists are easy accessible 
and therefore they are the first health care professionals to be contacted if necessary. 
Community pharmacist in the RESPECT study detected many patients who had a 
medical condition but were not taking a medication to treat it (untreated condition). 
Figure 10 shows this category which was the third most frequent of PCIs (12.4%). 
Appendix AD shows that the pharmacists intervened effectively to resolve these 
problems by their recommendations to GPs to 1) initiate new therapy (add new 
medication) (n=97 out of total 357). This intervention was accepted by GPs in 79% of 
cases (Table 12), or 2) contact other HCPs (refer patients to GPs or other health care 
providers) (n=70) and 3) monitoring (n=68). It was decided in our new classification to 
become "Fail to receive drug" (Appendix V). 
Community pharmacists in the RESPECT study detected patients who required 
"follow-up" (monitoring) which is the fourth most frequent of the PCIs (figure 10) and 
the following up of the results with GPs and other HCPs was high in frequency 10% 
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(n=299). This category includes: I) Observational monitoring of patient problems  such 
as side effects with cooperation with GPs and the others health care professionals, II) 
Requesting biochemical monitoring (e.g. urea and electrolytes) and III) " therapeutic 
drug monitoring"  (TDM) when the patient was using a drug with a narrow therapeutic 
index such as digoxin and theophyllin and carbamazepine. The importance and the 
benefit of biochemical monitoring and measuring plasma drug concentration (TDM) to 
achieve optimised dosage regimen by community pharmacist had been shown in many 
studies (Hawksworth and Chrystyn, 1998). Community pharmacists in the RESPECT 
study were often requesting measurement of blood pressure (BP) by GP or nurse. Other 
non-clinical issues under the follow-up category was issuing of the repeat prescription 
and checking the patient’s appointments with hospital and surgery. 
It was also decided that in our new classification the TDM category could be 
condensed with the "follow up" category to become monitoring required (Appendix V). 
Figure 10 shows the fifth most frequent of the PCIs to be the pharmacist request 
to "assess patient problems" by GPs for conformation diagnosis and subsequently 
rationalise medications they used (unnecessary drugs used for a long time without any 
physician review to assess their indication) which was important and the percentage of 
this category was 9% (n =271). This has implications not only in the health system 
(prevented harm caused by medication side effects), but also in reducing the financial 
burden by removing the unnecessary drug (reduce medication wastage) from the repeat 
prescription. It was decided that this category could be easily condensed with the review 
medication category (Appendix V). 
 One of the major roles of pharmacists who are providing PC for the elderly as in 
the RESPECT study is to encourage patient compliance. Poor compliance is a big 
problem particularly with ageing for several reasons such as 1) Polypharmacy, 2) 
experience of side effect, 3) impairment of memory and physical function (frailty and 
  93 
dexterity) (Corlett, 1996, Grant et al., 2003). In addition, poor adherence in elderly 
patients clearly has an effect on receiving sub-optimal therapy and  the financial cost of 
in patients also is very high (Lowe et al., 1995). 
Figure 10 shows PCIs due to poor patient compliance were the sixth highest 
percentage of PCIs at 9% (n=257). Appendix AD reveals that community pharmacists 
in the RESPECT study endorsed several types of recommendations to help patients with 
a non-compliance problem such as educate the patient regarding drug therapy and 
diseases or use of  a compliance aid such as nomad tray or drugs calendar  (n=74 out of 
total 257), follow-up patient compliance for example monitoring of pharmacy 
medication record (PMR) (n=40), simplifying drug regimen ( change the dose ) (n=10), 
change drug to sustained release ( change medication formulation) (n=13), and using an 
ordinary bottle or loose tablets instead of child resistant containers to make it easy for 
arthritic patients to open them.  
Two cases presented in the RESPECT study show the importance of detecting 
and resolving PCIs related to poor compliance in elderly people. 
Case 1: Asthma incidence in elderly people is significant for about 10% and inhalers 
are the first line of treatment. The most widely used inhalers are MDI (metered dose 
inhaler).  In elderly patients, lower efficacy of inhalers is common due to the quantity of 
medication deposited in the lungs (Corlett, 1996). In the RESPECT study, elderly 
patients had a problem in using a MDI due to arthritis in the hands. The pharmacist 
recommendation was to switch MDI to an easy breath actuated inhaler which has an 
automatic spring mechanism stimulated by inspiration and less dependent on inhaler 
technique and this kind of intervention was scored highly by the study clinical panel and 
linked to improving the efficacy of patient management category. 
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Case 2: Elderly patients often have a problem to use eye drops for different reasons: 1) 
weakness and tremor of hands, 2) in-coordination, 3) poor eye sight, 4) hand arthritis, 5) 
fear of bottle touching the eye. Several solutions were suggested such as using auto-
squeeze or auto-drop to help the elderly in squeezing or positioning eye drops (Corlett, 
1996). In the RESPECT study, one of the participant patients had glaucoma (the most 
frequent cause of blindness in the elderly). It is important to use eye drops to treat the 
condition and prevent deterioration and the patient had difficulty using them. 
Pharmacists recommended a career or relative to help the patient with eye drop 
administration and also on some occasions the patient passed the pharmacy where the 
pharmacist administered the morning dose.  
The two cases above prove that providing PC services for elderly patients is 
possible when community pharmacists are included in elderly multidisciplinary care 
teams; however, continued training and support are necessary for pharmacists who are 
providing such services. 
Figure 10 shows the seventh most frequent PCIs as the determination of 
unwanted medications (Unnecessary, contraindicated or not-recommended) to prevent 
harm to patient due to their adverse effects, drug interaction and to reduce medication 
wastage. This lead to reduce financial burden of patient medication which was the major 
aim of many studies and governmental report (Hawksworth and Chrystyn, 1997, Hanlon 
et al., 2004, NHS, 2008). In the RESPECT study, the pharmacists identified around 6% 
(n =167) problems related to this category. Their interventions resulted in discontinued 
medication (n=38 out of total 167), changed dose (n=27), or switch to other medication 
(n=14).This implicates a potential cost saving for the NHS as a result of providing PC 
for those patients. 
Poor Health literacy or "poor patient knowledge" when the patient does not have 
enough knowledge or was not instructed or does not understand important issues 
  95 
regarding his/her medication, diseases and life style change needs. This category was 
also present at 4% ( n=113),  it was the eighth most frequent PCI, as shown in Figure 10 
and Appendix G. The most frequent challenges in studying health literacy are age and 
variation in level of education. In the US, "National Adult Literacy" found that more 
than half of adults had health literacy deficiency. In the elderly, poor knowledge is 
expected through cognitive impairment more than other ages. Thus, in a large sample 
size of 3260 patients aged  65 years or older, it showed that 22 % could not calculate the 
correct timing of  therapy dosing (Gray, 2003). 
Several studies demonstrate the impact of patients’ education about their 
medication and diseases in improving patient knowledge and subsequently in improving 
compliance and the efficacy of drug management (Al-Rashed et al., 2002, Sellors et al., 
2003). 
Figure 10 shows the ninth most frequent PCI is "prescriber problems" (poor 
concordance). These resulted from poor communication between pharmacist, patient GP 
and other health care professionals which can negatively effect patient management 
such as the issue of not enough supply of medication to cover the course of treatment, 
patient appointment cancelled by physician, waiting a long time for an appointment for 
urgent surgery and the availability of medication, also detected by community 
pharmacists in the RESPECT study, with 2.36% (n= 68) of PCIs. 
One of the important PCIs and the tenth most frequent determined by 
pharmacists in the RESPECT study was related to "wrong dosing regimen" which 
included "high dose" 2.2% (n=65) or "sub-therapeutic dose" 2.1% (n=61). In our study, 
most of the interventions to modify dosing problems received a high score from the 
study clinical panel and were the most frequently judged by them as recommendations 
which could prevent hospital admissions. This category needs high confidence and 
scientific knowledge of pharmacists to changes particularly with older people. 
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Drug–drug interactions are well defined when the patient is receiving two drugs 
well known to cause frequent medical problems or symptoms due to their interaction. 
Although, this category is very common in the elderly due to multi-drug therapy and the 
fact that the current computer system in pharmacies gives an alert automatically if there 
any drug-drug interactions, this was one of the minor PCIs as eleventh most frequent 
(Appendix G) 2% (n=50 out of 2879). This could be due to many computer prompts 
being for minor interactions which the pharmacists can override and is further evidence 
of poor documentation of pharmacists in the RESPECT study. 
The rest of the PCIs in Appendix G were less frequent such as "Cost 
effectiveness" which was when the patient was using a high cost drug which had 
cheaper alternative with the same efficacy and safety profile (e.g. generic version). This 
category was low in frequency (1%) which demonstrates that pharmacists taking part in 
the RESPECT study did not pay more attention to medication cost in order to find a 
lower cost drug without affecting drug safety and efficacy. This may be because the 
community pharmacies at the time of the RESPECT study was paid for the amount of 
drug dispensed not for the quality of services they provided. Furthermore, elderly 
people usually resist any modification to their medications. 
In Figure 10 the category "Fail to receive drug" (1%) was classed as when the 
patient had a medical condition resulting from his/ her not receiving a drug. It was 
suggested that the frequency of this category could be added to the "untreated condition 
" category as (See Appendix V for new PCIs classification by the researcher). 
One of the least frequent PCIs in Appendix G which include " improper drug 
selection"  (1%) when the patient has a medical condition because he/she is  taking the 
wrong drug which is not effective for that indication, or the patient has an allergy for 
that medication. In our new classification, the previous category was condensed with 
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the category " drug used with no valid indication"  to become " improper drug selection" 
. 
 Finally, the others category in Appendix G which includes the PCIs related to 
social problems 0.13%, was when the patient has PCIs due to any type  of social issue 
such as the loss of partner which may negatively affect patient compliance and 
subsequently the efficacy of his/her management. 
Overall, these large numbers of PCIs ( >2879) emphasise the potential negative 
impact of these problems on elderly patients if the community pharmacist in the 
RESPECT study had not picked up this huge number of PCIs and how much money 
they are saving for NHS if they can resolve them or refer them to other HCPs who can 
do  so. 
The analysis of PCI frequency over the period of study demonstrates that there 
were reductions in the number of PCIs over the study period (Figure 11, 12 and 
appendix AE) which can be interpreted that the community pharmacists in the 
RESPECT study started effectively to determine PCIs during the first 3 months of the 
study. After that, the frequency of PCIs declined regularly until reaching the minimum 
point in month 12. 
 This leads to the conclusion that additional training is beneficial for community 
pharmacists who participate in such a study. Furthermore, the lack of motivation and 
financial benefit in relation to the time taken to make the interventions may have 
explained the tail-off. Moreover, because pharmacists worked mainly with single GPs 
or practices and the patients were also registered with a single pharmacy as well, the 
opportunity was provided to discuss each of the patients registered with the pharmacy 
directly with the GP, who was supposed to give the necessary medical background 
information to the pharmacist. However, it was only when the community pharmacists 
knew, and had details of the patient’s medical condition and prognosis that they were 
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able to intervene effectively and to suggest new therapy or other recommendations. It 
may be that poor cooperation from the GPs to provide patient information to the 
community pharmacists in the RESPECT study, led to insufficient information being 
provided and subsequently the decline in PCIs detected over the study intervals. 
Overall, most of the previous PCIs in the RESPECT study are potentially 
preventable and are relevant not only to the drugs themselves but the way in which they 
are prescribed, monitored and administered by the patient or carers. 
4.1.3. Community pharmacists interventions in RESPECT study 
 
In the RESPECT study, the community pharmacists made their intervention with 
cooperation (shared) with general practitioners. Due to the substantial financial 
resources of the RESPECT study, our study shows a higher proportion of actual 
community pharmacist interventions (2518 after excluding " no intervention"  category )  
(Table 10 and Figure 13) compared to the study by Hawksworth et al.,(1999) (1503) 
which was not resourced and where pharmacists acted voluntary.  
The classification of types of intervention made by community pharmacist in the 
RESPECT study was one of the main objectives of this study. In this study, we used the 
same reliable and valid classification as by  Hawksworth et al., (1999).  
It was observed that monitoring was the most frequent pharmacist 
recommendation in the RESPECT study 32.19% (n=297 out of total 2879 which made 
up of the 2518 actual intervention and 361 " no intervention"  category). Further sub-
classification for this category into five subcategories (Figure 14): 1) Biochemical 
monitoring, 2) Therapeutic drug monitoring (TDM), 3) Subjective monitoring, 4) 
Objective measurements and finally 5) others.  
There was a high frequency of this category of pharmacist intervention due to 
change in pharmacokinetics with ageing especially with the decline in renal function, 
therefore many drugs doses need to be tailored to patient renal function measurements 
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before use with the elderly. Furthermore, hepatic flow is reduced with advanced age; 
therefore patients with hepatic problems need to adjust their medication doses.  
Pharmacist recommendations for therapeutic drug monitoring (TDM) for 
particular drugs with a narrow therapeutic index to optimise drug therapy were minor in 
frequency (n=5). This was unexpected for this category because elderly patients need 
close monitoring of the medications with narrow therapeutic index such digoxin and 
phenytoin. Subjective monitoring includes monitoring drug efficacy, outcome of 
treatment and side effects. Finally, objective monitoring, such as regular measuring of 
blood pressure (BP) and peak expiratory flow rate (PEF) in asthma or chronic 
obstructive pulmonary disease (COPD) patients. 
“No intervention” category occurred in 13% (n=361) of total cases which may 
be due to the expectation of the GP response from previous occasions, which is 
discussed at the end of this section. 
Counselling was the second type of actual interventions provided by community 
pharmacists in the RESPECT study. Patient education by pharmacists has become one 
of the general roles of community pharmacists which can be sub-classified also into 
four main categories (Figure 15) Firstly, educating patients about their medication 
(counselling about drug information). Secondly, encouraging patient compliance by 
face-to-face education. Thirdly, helping the patient with poor compliance how to use a 
compliance aid such as dosette box, medication chart calendar and nomad tray. Fourthly 
was training on proper inhaler technique. Finally, " others"  which included counselling 
the patient on life style modification, for instance encouraging healthy diet and exercise, 
alcohol and smoking cessation. The high frequency of the "counselling required" 
category was due to problems related to ageing such as cognitive and memory 
impairment causing patient confusion, chronic high morbidity from multiple diseases 
which need multiple drug therapy with subsequent anticipation of adverse effects due to 
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polypharmacy and, finally, impairment of physical function which leads to inability of 
the patient to self-medicate and hence make proper use of the drugs. For example, 
elderly patients using inhalers usually have a problem with their efficacy because of 
their inability to use them properly due to their physical weakness, memory impairment 
and poor coordination of inhaler technique. 
The third most frequent category was to change dosing when there was a 
mistake with the GP’s prescribing (high dose or low dose) which emphasises the 
pharmacist’s ability to detect and resolve this type of PCI. This needs pharmacists with 
more confidence and knowledge in pharmacokinetics and pharmacodynamics of elderly 
to recommend optimal dosing of the elderly. The recommendation to change dosing of 
therapy either by increase or decrease of dose was the most frequently recommendation 
accepted by GPs (n=164) this is because that SPSS drug list provided us with the 
proportion of implemented interventions for this category. 
In Table 10 and Figure 13, community pharmacist recommendation to " added 
new medication"  was the fourth most frequent intervention type. The reasons for this 
intervention was because either pharmacists were detecting untreated medical 
conditions or to improve efficacy of management by adding  a new drug to another the 
patient was already on to improve the efficacy of each or to treat a side effect of  the 
regular medication the  patient was using. 
The category "referral to a GP or other health care provider" (contact other 
health care providers) was the fifth highest intervention by pharmacists in the 
RESPECT study. This has a positive impact when the patient problems need special 
care (advance services) which is only available either at the surgery or hospital, such as 
therapeutic drug or biochemical monitoring. This is to be expected when the 
information is shared between pharmacists and GPs. However, reviewing the PCPs in 
the RESPECT study shows that when some pharmacists detected and documented PCIs, 
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they just sent them to the GP without any recommendation. Other pharmacists identified 
a problem and because they were not sure what the clinical issue was or had no 
suggestion to the GP, and they simply referred the patient to the GP with insufficient 
documentation to help. 
In our study, further re-categorisation of this category led to three sub-categories  
Figure 16 and Appendix L:1)  Referral to GPs ,which was highest sub-division 70% 
(n=133), followed by 2) nurse around 12% (n=23) when the patient needed to have a 
review with the asthma nurse or referral for the regular monitoring of blood pressure, 
biochemical and therapeutic drug monitoring and ,finally, for 3) other HCPs  such as a 
consultant for elderly, podiatrist and optometrist 17% (n=34), as in the case of checking 
renal function, patient feet  and eye sight. 
A switch to other medication for the same indication was 5.2% (n=152) (sixth 
highest intervention type) of all the recommendations by pharmacists in the RESPECT 
study. The reasons for that were to improve the efficacy of patient management, 
unavailability of drugs, to avoid side effects and, finally, reducing the cost of 
medication. 
When they began the RESPECT study, " Review of patient medications"  
(n=113) is a general term for the community pharmacist interventions which aim to 
rationalise medication use (to avoid duplication, it was decided in the new classification 
by researcher to condense the community pharmacist recommendation to " assess 
indication"  2% (n=56) and " review of patient medications"  4% (n=113) into one 
category to become " review medications"  6 % ( n=169) ( Appendix V). 
Sharing the review of patient medications between the GP and the pharmacist 
enhance the ability of the latter to detect and resolve PCIs. (Zermansky et al., 2001, 
Krska et al., 2001, Sorensen et al., 2004, Lenaghan et al., 2007). In 2000, a NHS 
document illustrated that patients usually find it convenient to have the community 
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pharmacy very close to their GP’s surgery. This is a way for better cooperation between 
community pharmacists and GPs for the benefit of their shared patients (NHS-Future, 
2000) .  
There were pharmacist less frequent interventions in the RESPECT study not 
related to clinical issues; however, it is important to improve the efficacy of 
management of the therapy, such as" solve supply problem"," providing enough supply 
for the patient"  " providing information about drug manufactures to prescriber" and " 
help to arrange and remind the patients about appointments and due date for their 
repeated prescriptions". 
The recommendation for a change of therapeutic dosage regimen such as 
"change frequency" and " change time of administration"  and change of medicine 
formulation were important parts of pharmacist interventions in the RESPECT study. 
These interventions were initially aimed at improving patient compliance and 
concordance by simplifying drug regimens such as using a once daily regimen or 
changing the time of administration to morning or evening time to tailor it to the 
patient’s convenience."  " Change medication formulation"  is an important intervention 
in elderly people as they often have poor compliance and adverse drug effects, so a 
change of formulation to a controlled release or sustained release preparation (C.R or 
S.R tablet) will help patient compliance. In addition, using coated tablets will help to 
avoid gastro-intestinal adverse effects. Furthermore, elderly people usually suffer from 
difficulty in swallowing the tablets, so to change the drug formula to either syrup or 
intravenous may help to solve this problem (Corlett, 1996). 
As mentioned earlier the Table 13 shows the" no intervention" category in the 
RESPECT study was a significantly frequent category (n=361 out of total 2879) which 
was later judged by the study clinical panel as interventions which could be detrimental 
to the patient’s management. No interventions were made in many cases because there 
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was no further action required or the pharmacist just listed the information available 
from the outcome of a previous intervention or there was not enough information (poor 
documentation) or it may be that pharmacists actually had not intervened effectively to 
solve the patient PCIs.  
Lack of pharmacist comment on the reason why he/she had not intervened 
effectively to solve the PCIs was a point of discussion in many studies. For example, the 
study by Paulino et al., (2004) shows that in many cases when PCIs occurred and were 
reported to physicians, the drug was not changed, with no action from the physicians 
and therefore pharmacists considered that to be tolerable and not avoidable. The same 
may have occurred in the RESPECT study where similarly pharmacists had made  a 
previous intervention which were not implemented by the GP and which resulted 
therefore in a high frequency of " no intervention"  category (n=361 cases out of total 
2879). The other clinical interventions of the community pharmacist with the GP are 
listed in Table (10). 
In the study by Hawksworth et al., (1999), " change the dose"  was the most 
frequent intervention, next to that, " alter formulation"  was the second, then " 
counselling"  and, finally, " switch to other medication" . Meanwhile, in a study by 
Krska et al., (2001), they did not mention intervention classification because they were 
concerned about the classification of the  reasons for the pharmacists’ interventions. 
 Overall, the community pharmacists in the RESPECT study were trained to 
provide a pharmaceutical care for older people but the interventions were not optimal in 
many circumstances. This may be because this was the first time that the participant 
pharmacists had provided such care and they showed reluctance to provide appropriate 
clinical interventions. This actually reflects the levels of pharmacist at the time of the 
RESPECT study. Therefore, the NHS in 2000 published a government strategy for" 
pharmacy in future" which aims to modernise pharmacy services in England. Quality of 
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service was once again highlighted in the Lord Darzi NHS review to improve the 
quality of services within the department of health primary and community care (NHS-
Future, 2000, Darzi, 2008, NHS, 2008). In 2003, pharmacists also began training to be 
supplementary prescribes (over 900 are registered in 2008 as supplementary prescribers 
in England). Independent prescribing was also introduced in 2006 and over 300 
pharmacists are registered in 2008 in England as independent prescribers (NHS, 2008). 
In 2006, a national framework for pharmacists with special interests (PhwSIs) was 
developed to provide the potential for people to gain better access to more specialised 
services in convenient locations. Pharmacist can provide new services for people 
including elderly people with long term conditions (LCTs) ( appendix AC) who require 
monitoring and adjustment of their medication dose such as older people who take 
warfarin (NHS, 2008). 
4.1.4. Implementation by GP of pharmacist recommendations 
 
 The UK Government believes the effective professional relationship between the 
pharmacist and other Health care providers is important for the development of 
pharmaceutical services (Darzi, 2008) 
The implementation by GPs of pharmacists’ recommendations on 
pharmaceutical care plans (PCPs) is an important consideration in many studies. 
Figure 17 reveals that more than 80% of community pharmacist recommendations 
were accepted by GP after exclusion of the two categories " not sufficient 
information"  and " not applicable" ( n=891) compared to 96% in by Krska et al., 
(2001) study. 
One of the main objectives of our study was to find out whether the GP 
implemented the community pharmacist’s recommendations. However, it was difficult 
for the researcher to quantify the exact implementation of the community pharmacist’s 
recommendation due to the lack of information about the implementation processes. It 
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had been agreed that the only source evidence of implementation was the drugs list in 
SPSS which only displays name, strength and formulation of regular drugs in each 
interval of the RESPECT study, as shown in Appendix N. This would only help to 
know the implementation of the following recommendations related to change of 
therapeutic regimen (Table 12 and Figure 19): 
a. To change the dose. 
b. To change drug formulation. 
c. To add new medication. 
d. To switch to other medication. 
Moreover, the PCPs were used also for the same purposes to check 
implementation. The analysis reveals that the most frequent recommendations 
implemented by GPs were for the categories related to changed therapeutic regimen 
compared to other types of pharmacist’s recommendation (Table 11 and Figure 18). The 
reason for this was that most available information about implementations was only 
about those categories of change to therapeutic regimen (SPSS drug list). 
This demonstrates that pharmacists made good interventions which could 
change the prescribing of GPs due to the high percentage of implemented 
recommendations in these five categories, however, poor documentation regarding GPs’ 
implementation was the reason for the high percentage of the two categories  " not 
applicable"  and " not enough information"  which had been excluded  (Hilton, 2006) 
( for total results of implementation see Appendix M). 
Therefore, the research team of this study agreed that a further analysis should 
be made of for all interventions with unknown outcomes, namely, the two categories " 
not applicable" and " not enough information" by using the clinical panel interventions 
re-classification and the scoring (Score ≥7 of the two categories intervention prevented 
harm and improved the efficacy of management) for the same interventions as shown in 
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tables 13 and 14. These illustrate that 760 out of a total of 1628 were categorised by the 
panel as interventions that could have prevented harm to the patient and 578 which 
improved the efficacy of management, 14 counted as interventions which could be 
detrimental to the patient management and 214 as interventions for information only (no 
clinical issue specified). Insufficient information category also was significant (62 out 
of total 1628). Furthermore, 170 out of total 1628 (10.44%) of the" unknown outcomes" 
were given a score 7 or more by clinical panel which indicates that there were 
significant proportion of these interventions that could have the potential to prevent 
hospital admissions. 
 This shows evidence that there were very good interventions by pharmacists. 
However, it could be that the outcome measures used by the RESPECT study were not 
as useful as those used in this study by the introduction of a clinical panel. However, in 
this case, the lack of documentation of information still proved to be a major barrier to 
the optimum outcome data. 
It was really difficult to ensure the implementation by GPs of pharmacist 
recommendations in other categories such as monitoring and counselling due to 
insufficient information to decide whether GPs accepted or rejected pharmacist 
recommendations.  
Furthermore, there was a mistake in the structure of the PCPs form because 
there were no fields showing whether recommendation were accepted or rejected by 
GPs and also their comments. Also, in the case of pharmacist’s recommendations 
rejected by GPs, they should document in the PCPs why they are not implementing 
those recommendation. 
The influence on positive patient outcomes of the implementation of such 
recommendations in the health care system was difficult to estimate and also if GP 
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prescribing had been changed, as there was not sufficient clinical information recorded 
in the study about the outcomes to fully answer the question. 
We are confident that community pharmacists in the RESPECT study were 
frequently making appropriate recommendations which could be implemented by the 
GPs as they are experts in drug therapy; however, a flaw in the structure of the care 
plans led to results which showed poor documentation and a lack of follow-up in the 
design. 
The study by Hilton, (2006) who investigated inappropriate prescribing in the 
RESPECT study by using Medication Appropriateness Index (MAI) mentions that 
effective care plans mean that pharmacist interventions improve GPs’ prescribing. If 
there are few interventions on the care plans then prescribing can not be affected as a 
result.  
Follow up analysis of the care plans of the RESPECT study by Hilton, (2006) 
shows that 74% at month 12 have no action for the GP and nearly 50% of care plans 
have no issue for the GP to resolve. One of the important factors analysed by the 
RESPECT study is the uptake of a pharmacist recommendation (implementation) by the 
GP or if the GP had paid no attention to it, so that prescribing will continue as it was 
without any alteration. The review of care plans of the RESPECT study also shows that 
the GPs make little comment on their opinion regarding the pharmacist interventions. In 
fact, most of them just sign on the care plans.  
Hilton, (2006), mentions there was also a mistake in the construction of PCPs 
because there is no field for GPs’ positive or negative agreement or their comments 
regarding PCPs. This made it difficult to know the uptake of GPs who took action on 
pharmacists’ recommendation of a change in their prescribing.  
In addition Hilton said that, they were confident that there was a discussion 
between participant pharmacists and GPs in the RESPECT study. However, there was 
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no information about that documented in PCPs. This will directly affect our judgement 
about the implementation process and subsequently the study result regarding this issue. 
For example, if the pharmacist documented in the PCP that the patient was taking 
contraindicated medication and recommended it to be discontinued, and then the GP 
called the pharmacist to tell him that he was aware of this. However, there is no other 
choice. Therefore, the physician’s comments should be documented in the PCP so it is 
important that this issue is taken into account when constructing the care plans form. 
 Fortunately, at the time of our study major initiatives were emerging from the 
NHS regarding this matter (Darzi report and white papers).The new White Paper " NHS 
connecting for health" (2008) mentions that the UK government is to arrange for 
electronically documenting the information on pharmacist interventions centrally, as 
part of promoting healthy life styles, to support recording (documenting) of information 
by the pharmacist. This will help in identifying the community pharmacist’s 
contribution to public health (NHS, 2008). 
Hilton (2006) also had the same difficulty as in our study to estimate an 
implementation percentage in the RESPECT study. She concluded that the intervention 
must be eliminated if there is no information about whether the GP had implemented 
the pharmacist recommendation as she could not justify the recommendation because 
the GP did not document any comment about the intervention. 
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4.1.5. Re-categorisation and scoring of pharmacists interventions                  
outcome by clinical panel 
 
            In order to evaluate the quality of PCP, it was decided to introduce the study 
clinical panel to categorise and score the pharmacist intervention produced. This method 
had been used before to assess the interventions made by community pharmacists 
during the intervention period, as in Hawksworth et al., (1999), Needham et al., (2002) 
and Buurma et al.,  (2004) (Appendix AB). 
Because the study was done in the community, two community clinical 
pharmacists and only one hospital clinical pharmacist were chosen to investigate each 
community pharmacist intervention in the RESPECT study and to classify their 
importance, as in the study by  Hawksworth et al., (1999) (Table 15) . 
In order to reduce the workload, the panel excluded PCPs with insufficient 
details to help their judgement. Each intervention in the care plans of community 
pharmacists in the RESPECT study needed to be assessed by the independent clinical 
panel over a period of around six months. At the first meeting of the clinical panel, they 
attended a briefing presentation on power point by the pharmacist researcher at which 
the following points were discussed: 
• Background information about RESPECT trial. 
• Short brief about our study. 
• Classification of PCI and intervention types used. 
• Clinical panel roles in this study (Figure 9). 
The clinical panel met on 10 occasions and discussed and categorised each of the 
interventions. It was decided at the first meetings to add two new categories, " no 
enough information to classify"  and " intervention for information only"  to the 
Hawksworth et al., (1999) classification and reordered the categories as shown in Table 
13 into: 
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1. Prevented harm to patient. 
2. Improves the efficacy of management. 
3. Detrimental to the management of the patient. 
4. For Information only (this category not classified only and tested by agreement 
to Yes or No). 
5. Not sufficient information to classify. 
In order to measure the community pharmacist outcome in the RESPECT study 
and the importance of each community pharmacist intervention, It was also decided to 
introduce the 1-10 points to measure the confidence of the clinical panel in each 
intervention the researcher had put into the three categories 1) improved the efficacy of 
management, 2) prevented harm to the patient management and 3) Detrimental to the 
patient management, as shown in Table 16 of the results. 
Before the panel began the scoring of the interventions, each point of scoring 
was defined by the clinical panel members, as shown in Table 9 and also they decided 
that the score 5 which would be classed as a value where the panel could not agree on a 
value for ranking and in which category. An external assessor who was a senior clinical 
hospital pharmacist was recruited to independently judge any intervention scored 5 as it 
was usually the panel clinical hospital pharmacist who could not agree with the 
community pharmacists (Table 20). 
It had been agreed by the study researcher and the clinical panel that any 
pharmacist intervention would be counted as an " appropriate intervention"  when it 
gained a score ≥ 6 (6-10) for the two categories " improved efficacy"  37% (527 out of 
1243) and " prevented harm to patient management"  42% (336 out of 897). These 
results are comparable to the 48.8% of total interventions which were judged to have a 
positive impact on the health care system in the study by Hawksworth et al., (1999). 
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The clinical panel in the Hawksworth et al. study linked 48.7% of pharmacist 
interventions to improved efficacy of patient management and 64.6% as interventions 
which prevented harm to patient management compared to 43% as prevented harm and 
31% as interventions which improved efficacy of patient management and only 3% 
which could be detrimental to the patient management in our study (Figure 21 and 
Table 15). 
In several studies, prevented or reduction of hospital admissions was one of the 
most important measures of pharmaceutical care outcomes (Lenaghan et al., 2007, 
Goettler et al., 1997). In the RESPECT study, one of the important factors which can be 
quantified in this study is the influence of the pharmacist interventions in preventing 
hospital admissions. As shown in tables 19, the clinical panel judged that 367 hospital 
admissions could be prevented by pharmacist interventions in the RESPECT study 
which is the total of the interventions which received a score of 7 or more (7-10) from 
the clinical panel for the two categories " prevented harm to the patient management"  
and " improved efficacy of management". This presents a huge financial saving to the 
NHS. The interventions that could prevent a hospital admission are only possible 
because of the presence of the community pharmacist clinical output and these are not 
possible without a pharmacist. 
It is usual custom and practice that the amount calculated for a hospital 
admission takes into account only the cost of hospital stay (direct cost). However, the 
estimation of indirect cost is very complicated because of the required information 
needed which is difficult to access (indirect cost) (Goettler et al., 1997). 
 In our study, saving made by reducing hospital admission can be estimated, 
while the potential cost saving from prevented harm or improved efficacy is not 
possible to quantify but it is evident that the community pharmacist can provide a 
considerable cost saving contribution to the NHS, even though they did not have full 
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access to the patient’s clinical record. Figure 25 shows how the community pharmacists 
in the RESPECT study could intervene effectively to save money for the NHS 
(£504,625) if hospital admission was prevented by providing PC for elderly patients. 
The total value was calculated by using the direct cost of hospital stay per night at the 
time of the  Hawksworth et al., (1999) study.  
            Elderly patients are at risk of longer hospital stay than the rest of the population. 
The major factors for prolonged stay in hospital in advanced age are stroke, confusion 
and falls. Even though these factors are important, the most important influence on the 
length of hospitalisation is the medical reason for hospital admissions (Maguire et al., 
1986). For example, the current average length of hospital stay at a local hospital for the 
elderly in West Yorkshire is 11 days. However, the cost depends on diagnosis. For 
example, an acute admission with chest pain (cardiac or respiratory) would cost the 
primary care trust (PCT) £921 plus £192 for every day over 7 days. Therefore, the 
average could be £1689 per case (Source: personal conversation with local hospital in 
West Yorkshire., 2008). If we used this information in our study, the estimated cost 
saving for the NHS due to community pharmacist interventions in the RESPECT study 
was approximately £620,000. 
In the study by Goettler et al., (1997), they assumed that approximately 5-6% of 
all hospital admissions are caused by ADR. Appendix R shows that the most common 
pharmaceutical care issue in our study which could leads to hospital admission were 
adverse drug reaction (ADR) (n=37 out of total 170), followed by poor compliance 
(n=24), then untreated condition (n=19) and efficacy of medications (n=15). 
It is interesting that before the decision from the panel on how to classify 
hospital admissions; initially the researcher was looking from a different angle for this 
category (interventions that could prevent hospital admissions) from the clinical panel. 
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 Initially assessment was made by the researcher on the risk of hospitalisation if the 
pharmacists had not detected PCIs and on the clinical value of the intervention made by 
pharmacists on the basis that the most serious PCIs such as warfarin or digoxin 
overdose or risk of fall due to the drowsy effect of using of benzodiazepine or anti-
depressant may have the most tendency to lead to hospitalisation (Figure 20 and 
Appendix P).  
Even though the quality of the pharmacist’s documentation of the interventions 
was poor because of the lack of information provided, the number of interventions 
judged by the clinical panel as "prevented harm to the patient" is high. This can be 
interpreted also as a form of cost saving to the NHS because it prevented the burden on 
NHS resources which would have been required if harm was caused to the patient. 
The clinical panel did not give any intervention the maximum score of 10, so 
that means that most of the interventions had not reached 100% confidences of the 
study panel. Also, most of interventions had not reached the standard level of 
appropriate interventions, which had been agreed by the panel to start from score 6 for 
the two categories "prevented harm to the patient" and " improved efficacy of 
management". 
4.1.6. Drugs involved in the RESPECT study 
 
           In our study, 9823 prescribed regular drugs in T1, T2, T3 and T4 (T5 was 
excluded because of defect in data collection at this period) with mean (SD) of 7.1, 7.3, 
7.6 and 7.9 (2.6, 2.9, 3 and 2.9) respectively (Appendix Y). This shows that there was 
increase in number of medications prescribed throughout the four study periods. This 
may be due to pharmacist intervene effectively to detecting many PCIs which needs to 
add new medication such as untreated conditions which was the third most important 
PCI determined by community pharmacists. Moreover, ADRs which was the most 
common PCI in the RESPECT study required new medication to be added moderate the 
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severity of side effects, if the physician decided to continue with the same medicine 
because there were no other options. It is interesting that at the time of the RESPECT 
study, the pharmacists were paid for amount of drugs dispensed not for the quality of 
services provided.  
The statistical comparisons of the number of the drug prescribed in the four 
intervals shows that there were significant changes in the number of drugs prescribed in 
different time of study period (Appendix Z). Figure 27 shows that, the most frequent 
medication category (according to BNF classification) involved in this study was 
category 2 (cardiovascular system drugs), followed by category 4 (central nervous 
system medications), following that was category 1 (gastrointestinal systems) and 
category 10 (muscle, skeletal and joint disease) was the fourth most frequent category 
(8.66%).  
Non-steroidal anti-inflammatory drugs (NSAIDS) were the main contributor 
drug group which cause PCIs in the elderly, being responsible for 28% of hospital 
admissions in a study by Cunningham et al., (1997). In the RESPECT study, NSAIDS 
drugs were the second most frequent types of drugs involved in PCIs (10%) after 
cardiovascular drugs (category 1) as shown in Appendix AA .In a study by Krska et al., 
(2001),  it was found that cardiovascular (CVS) (category one in BNF) were associated 
with the most frequent PCIs, particularly diuretics (26%), nitrates, calcium channel 
blockers and potassium channel blockers (10%) and angiotensin converting enzyme 
inhibitors (ACE-I) and other anti-hypertensive medications (7%). This finding was the 
same in our study where CVS drugs were the most commonly involved (34%). 
Furthermore, in both studies (RESPECT and Krska et al.) there is a requirement for 
monitoring associated with the use of diuretics which includes biochemical monitoring 
for renal function, electrolyte and potassium level, and hence the necessity for 
monitoring disease progression.  
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There are further comparisons, for example inhaled therapy (bronchodilators and 
corticosteroids) for asthmatic patients which were commonly associated  with " the need 
for education"  (Krska et al., 2001). In the RESPECT study, asthma medications 
(inhaler therapy) were the fourth most frequent drugs involved (Appendix AA) 
(7%).This illustrates the need for counselling on proper inhaler technique of inhalers 
(n=37 out of total 288) 12.8% of total cases of counselling (Figure 15). 
The Hawksworth et al. (1999) study shows that there was an inverse relationship 
between the number of drugs prescribed and the number of interventions in each of the 
study intervals. In contrast, this study could not show that relation.  
It was difficult to calculate the exact cost saving for the NHS as a result of a 
reduction in the number of drugs prescribed due to the removal of medicine from the 
repeat prescribing record over the study intervals, because of the missing data in the 
SPSS drug list.  
A lot of medications prescribed at T5, T4, and T3 were missing from the list and 
there was also drug duplication and many patients missing from the list. However, the 
size of the study sample (760) and the huge number of PCIs detected by pharmacists in 
the RESPECT study are sufficient to predict that there is a reduction in the number of 
drugs particularly between the two intervals T4 and T5, (figure 26). This reduction is 
due to several types of pharmacist intervention which include discontinuing unwanted 
medications (n=130), review medications to assess the drugs indication (n=113), switch 
to alternative medication or alternative formulation ( n=152) and (n=32) respectively 
(Table 10). Subsequently, huge financial saving for the NHS. 
4.1.7. Limitations 
 
There are several limitations to this study which caused difficulty in analysing 
and evaluating the community pharmacist interventions in the RESPECT study. The 
major limitation directly affecting this study was the lack of information provided. 
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There were only three sources of information namely: "pharmaceutical care plans"  
"drugs prescribed list in SPSS" and" patient main problems list". 
Moreover, not all recruited patients were included in the last two sources. 
Overall, community pharmacists participating in the study failed to document all the 
relevant details of clinical information about the PCIs they detected and the details of 
the interventions they made, including GPs comments about the pharmacist 
recommendation that they implemented and any parametric measurement requested and 
their results. The clinical panel also found that they had difficulty making decisions due 
to lack of recorded information by pharmacist. 
The second important limitation for the researcher was the large amount of 
illegible hand writing and unclear copies of PCPs sent by fax from the community 
pharmacies which were difficult to read and then entering these in the Microsoft Access 
form. This consumed much of the time of the researcher (at least 4 months) and 
illustrated the limited experience of the pharmacists participating in the study. It also 
shows the importance of continuing training and support for professionals providing PC 
for elderly people. 
Hawksworth in the 1998 study said that "One of the major important limitations 
at present in the community pharmaceutical services system in the UK is that the 
community pharmacists are unlikely to know the medical diagnosis of the patients or 
other essential clinical information details. As a result, community pharmacists are 
unable to make full use of their information and expertise to predict PCIs and solve 
them"  (Hawksworth, 1998). The situation at the time of the RESPECT study for the 
community pharmacists was similar to that at the time of the previous study with regard 
to access of patient information, except for the community pharmacists taking part in 
the RESPECT study who were given the relevant information required for the study. 
However, since the RESPECT study there has been a development in pharmacists’ 
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access to patients’ relevant information which has improved pharmacist knowledge in 
the new community pharmacist’s contract. Nowadays, the NHS plan for community 
pharmacists is to be linked to the NHS net to help them in taking up the new roles in 
medicine management. Such roles would be optimised by electronic communication 
between GPs’ surgeries  and community pharmacies (Porteous et al., 2003). 
Many studies have shown the effect of the lack of clinical information about the 
patient and disease states which affect pharmacists’ confidence in their ability to 
provide PC and also the input the pharmacists usually give. In a study by Needham et 
al., (2002), 30 out of a total 130 clinical interventions were excluded as insufficient 
information had been documented  to allow judgement by the clinical panel. 
Needham et al., (2002) state that community pharmacists in their study had not 
recorded enough information about interventions for the panel judgement and this 
reflected  the current practice of UK community pharmacists. At the time of the study, 
they were not keeping any handwritten record only computerised medication records 
(PMR). However, the research team discovered this problem at an early stage and the 
researcher took the responsibility of reminding the pharmacists about the negative 
impact of poor documentation on the study outcomes. 
In our study, the more the information documented by the pharmacists, the 
higher the score given by the clinical panel. Furthermore, in some cases, it was difficult 
to interpret what had actually been written, which delayed the process of ranking by the 
study panel. In contrast, some PCPs recorded a large amount of information. However, 
much of this was not relevant. Moreover, PCPs analysis shows that in most of the care 
plans very few issues relating to the interventions are documented and this resulted in 
many interventions being rated lower than they deserved .The same  result emerged 
from the Hilton, (2006) study. 
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One of the main aims of our study was to find out whether the GP implemented 
the community pharmacist’s recommendations. However, the only tool, to determine 
this was the SPSS drug list (Appendix F) which can be used only in particular 
interventions related to therapeutic regimen change such as changing the dose, 
frequency, administration time or switch of medication therapy. 
In some cases, the PCPs were also used for the same proposes. In several 
instances, it was difficult to ensure the implementation of the pharmacist’s 
recommendation in the monitoring, counselling category due to lack of details about the 
GP’s comments and implementation. 
Furthermore, parametric measurements data such as blood pressure, blood sugar, 
cholesterol (lipid profile) and their follow-up by the pharmacists are usually the most 
important data to measure the clinical outcome in several studies (Wermeille et al., 2004, 
Al-Blowi, 2007). This allows the researcher to study the correlation between the 
influences of PCs provided and the clinical changes in the parameter. In the study by 
Al-Blowi, (2007), he compared HbA1c, blood pressure and  total cholesterol between 
the baseline and after 12 months to measure the outcomes of providing PC in patient 
with type 2 diabetes. Outcome measures could be easily quantified by using parametric 
measures, in which the target parameter measured, for example HBA1c is listed in 
tables on a regular basis (daily, monthly and annually) as evidence of the pharmacist’s 
follow-up as shown in Appendix AG. This is not achieved in the RESPECT study 
because there was no field for this parameter being measured to collect the data on the 
PCPs. Therefore, the information available does not indicate the progress in the patient 
medical problem (improvement or deterioration). 
In the RESPECT study, the pharmacists received two evening training 
workshops and a pre-work task which included case studies covering the medical 
conditions which usually affects older people. Meanwhile, Hawksworth et al., (1999) 
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arranged training for pharmacists who agreed to take part in the study on its the 
practicalities. In  Krska et al., (2001), only clinically trained pharmacists participated in 
the study. Overall, in all three studies, pharmacists who participated in them received 
training to provide PC for elderly. 
Despite the community pharmacists in the RESPECT study having received 
training in documentation of details of their interventions at the beginning of the study, 
they failed to document enough information in the PCP for a clinical panel assessment. 
This resulted in excluding 313 interventions due to lack of details on what may have 
actually been very good clinical interventions.  
Despite, efforts being made to get consistent feed-back from the clinical panel to 
re-categorise and grade the importance of the interventions in the care plans in the 
RESPECT study, the feed back from the panel recognised that there was inconsistent 
assessment and discussion which may have been affected by the different opinions of 
each member of the panel and their experiences of the current pharmaceutical care  
service which is provided by community pharmacists and their relationship with other 
HCPs. Moreover, it was also difficult to arrange frequent meeting times suitable for all 
members of the clinical panel which led to a restriction of the frequency of the full 
complement of clinical panel meetings.  
4.1.8. Outcomes of study 
 
Although the evaluation of the quality of the community pharmacists’ 
interventions in the RESPECT study by using the clinical panel is subjective, the same 
process was used by  Hawksworth et al., (1999), Buurma et al., (2004) and Needham et 
al., (2002) . However, in our study, we used a 1-10 point scale grading to measure the 
clinical panel’s confidence regarding the importance of each pharmacist intervention. 
 Overall, 96% of the community pharmacist interventions in the RESPECT study 
were judged by the clinical panel to have a positive outcome (improved efficacy of 
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management and prevented harm to the patient). Only 4% could have a negative 
outcome in patient management (detrimental to the patient management). These figures 
compare to 29.2% of intervention which were having a positive outcome in the 
effectiveness of therapy in Buurma et al., (2004), whereas in Needham et al., (2002),  
the panel judged 80% of community pharmacist interventions were likely to be 
beneficial. 
Our study demonstrated that when PC was provided to elderly patients in the 
RESPECT study this could help to reduce the hospital admissions and the number of 
visits to or by the patient’s GP through improved efficacy of patient management and 
the prevention of harm to the patient. It was difficult to calculate the cost saving to the 
NHS as a result of the reduction in the number of prescribed drugs over the study 
intervals because of the missing data in the SPSS drug list as a lot of medications which 
were prescribed at T5, T4 and T3 were missing, with drug duplication and many 
patients missing from the list. However, the community pharmacists’ recommendations 
to discontinue unwanted medicines such as drug used not recommended for elderly 
patients, contraindicated or not effective medication was 4.51%, which has a potential 
saving for the NHS. 
The results of our study emphasizes the importance of revising both the nature 
and period of post graduate training for community pharmacists who are going to 
provide pharmaceutical care for such studies and also paying attention to the direct 
relation between the levels of training pharmacists receive on the documentation of  
clinical details in the care plans. 
It was difficult to estimate the total effect of implementing interventions as there 
was not sufficient clinical information recorded in the study about the outcomes to fully 
answer this question. 
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4.2. Conclusion 
This study determines that the integration of the community pharmacist into the 
multidisciplinary health care team has a positive effect on elderly patients, with 
pharmacists becoming a useful partner in choosing and monitoring medication therapy.   
Our study highlighted that community pharmacists with an already established 
relationship with their patients and GPs can provide a more clinical role to support and 
improve patient outcomes in line with the requirements of the new White Paper on 
pharmacy (NHS, 2008). Furthermore, our research confirms that involvement of a 
pharmacist in elderly patient health-care within the setting of a community pharmacy, 
provided positive healthcare outcomes of their interventions and therefore should be 
encouraged in line with government thinking in the Darzi, (2008) report. 
This study also emphasises the effects of the lack of details in patient records 
with regard to patient medication and medical conditions on the community 
pharmacist’s confidence to provide optimum pharmaceutical service and restrict their 
outcome. This is the same as the finding by Needham et al., (2002).  
Poor documentation in the RESPECT study had a negative impact on the 
clinical panel judgement. It was observed that some pharmacists had documented PCPs 
as part of the standard part of dispensing and counselling process and we suspect that 
there was a variation between the pharmacists in what exactly was recorded in the care 
plans for the same type of interventions. The new White Paper (2008) illustrates that the 
national programme for information technology (IT) in the NHS connecting for health 
is helping the NHS, including community pharmacy, to increase efficiency of new 
services (medicine management) such as the electronic prescription system (EPS) which 
will reduce the need to visit the GP’s Surgery to collect repeat prescriptions and 
improve patient safety by reducing illegible or incomplete prescriptions (NHS, 2008). 
Darzi report also mentions that access to patient’s records will be very important in the 
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future to enable pharmacists to fully contribute to the government plans for personalised 
care records by 2010 (Darzi, 2008). Our study signified the importance of authorizing 
community pharmacists to access the full clinical information of their patients. This will 
enhance their clinical role in providing valuable pharmaceutical care to elderly patients 
at the point of new or repeat prescription dispensing.   
The new White Paper (2008), mentions that community pharmacists need to 
ensure that their skills, knowledge and training in providing specific interventions for a 
particular population including older people are up to date by incorporating these skills 
into the undergraduate pharmacist curriculum (NHS, 2008). This development would 
further necessitate the development of a competency framework to ensure that 
pharmacists working in this specialised clinical area (elderly care) provide a consistent 
level of service for patients in line with government expectations (Ainsworth, 2007). So, 
further development as prescriber in elderly care is possible for pharmacist practicing 
within their competency. Our study also emphasised the importance of revising the 
nature and period of post-graduate training (advanced level) for community pharmacists 
who are going to provide pharmaceutical care for elderly patients and raises the 
possibility of specialized postgraduate training for community pharmacists with a 
special interest in Elderly care as in pharmacist with special interest (PhwSI) model. 
There was some poor quality of provision of pharmaceutical care (PC) services 
in the RESPECT study. This may be due to the lack of motivation. Alternatively, the 
pharmacists are busy with dispensing because of the emphasis on volume of medication 
dispensed at the time of the RESPECT study in 2004, rather than the quality of service 
provided. This was before the new community pharmacy contract was introduced. 
However, currently under the new contract, community pharmacists are currently paid 
for the quality of services rather than for the amount of medication dispensing. 
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In the RESPECT study, there was a lack of confidence to provide PC. This may 
be due to the brief time and type of training and it may mean that these need to be 
reconsidered and specific new funding allocated for the pharmacist’s remuneration in a 
further revised contract to include provision of medicine management services by 
community pharmacists which need to be documented (Bradley et al., 2006). This is 
also proposed in the new White Paper (2008).  
The pharmacist’s documentation process in the RESPECT study was very poor, 
and the review process of medication in the majority of cases very basic. Several of the 
interventions presented to the clinical panel in fact even insufficient information in the 
care plans provided by the community pharmacists in the RESPECT study for the 
clinical panel to even acknowledge their significance. In several cases, very little 
information was provided that it was not even possible to evaluate whether the 
intervention would have had a positive out come or not. However, the need for 
additional training in pharmaceutical care which would have been beneficial in any  
future study needs to be taken into account and also any further training of additional 
support staff which would be needed to provide the service. Our study does suggest that 
when specifically trained community pharmacists (CPs) are included as members of the 
multi-disciplinary team with full access to patient records, they can intervene effectively 
to improve PC for elderly people in the community, providing additional support to 
keep them at home and out of hospital reducing NHS costs. This could be extended to 
include home visits to review their status and medications. 
This study follows on from the RESPECT study. The present findings of the 
RESPECT study on the improvement in healthcare outcomes, illustrate the major role of 
the trained community pharmacist in providing PC for older people. Community 
pharmacists also can play a crucial role in providing the safest use the medicines and in 
reducing inappropriate hospital admissions for those patients.  
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Our study illustrated the limited experience of the pharmacists participating in 
the RESPECT study and shows the importance of continuous professional development 
(CPD) in terms of continuing training and support for the professionals providing PC 
for elderly people because of the lack of consistent motivation throughout the study 
period. The quality of documentation, organising and listing of study progress data were 
found to deteriorate as the study progressed. 
It was difficult for the clinical panel and researcher to fully measure the 
objective outcomes of the study because the lack of patients information’s about 
parametric measurements follow up such as blood pressure, blood sugar, cholesterol 
(lipid profile) and Peak expiratory flow rate (PEF).   
One of the important aims in the RESPECT study was to reduce medications 
waste by regular review of the patient’s medication and subsequently, the lost financial 
burden of that medication. The new White Paper 2008 mentions that, the estimated 
current cost of unused or unwanted medicines exceeds £100 millions annually. 
Regarding the 1-10 scale to describe the panel’s confidence in the importance of 
each community pharmacists intervention and the use of score 5 for the external 
evaluator, the panel advised that it may be better for that score 5 to actually have been 
used in the grading process in any future study, and to use another symbol when the 
panel can not decided which score and category to be given.  
Finally, it was difficult to fully estimate the total effect of the implementation of 
all interventions in the RESPECT study as there was not sufficient clinical information 
for many interventions recorded in the study about the outcome to fully answer that 
question. 
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Appendix A 
 
Estimated growth of UK elderly population as a percentage of total UK 
population 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Projections from 2001 are based on 2000 mid-year estimates.  
Source: Annual Abstract of Statistics (ONS), Population Trends (ONS),  
Monitor PP2 98/1 (ONS). 
 
 
 
 
 
 
 
Age 65 to 74  
 
75 to 84  
 
Over 85  
 
Year 
Percentage growth 
 
1948 7.2 2.9 0.4 
1951 7.3 3.1 0.4 
1956 7.4 3.4 0.6 
1961 7.5 3.6 0.7 
1966 7.8 3.7 0.7 
1971 8.5 3.9 0.9 
1976 9.1 4.2 1.0 
1981 9.2 4.7 1.1 
1986 8.8 5.3 1.3 
1991 8.8 5.4 1.5 
1996 8.6 5.3 1.8 
2001 8.2 5.5 2.0 
2006 8.2 5.5 2.0 
2011 8.9 5.5 2.2 
2016 10.2 5.7 2.3 
2021 10.4 6.3 2.5 
2026 10.6 7.3 2.7 
2031 12.0 7.6 3.1 
2036 12.5 7.9 3.7 
2041 11.5 9.1 3.9 
2046 10.5 9.5 4.3 
2051 10.7 8.8 4.9 
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Appendix B: 
 
Drug- related problems and possible causes. Adapted from Cipolle et 
al, (1998) 
 
Need for additional drug  
New medical condition 
Chronic disorder (refill) 
Combination therapy for potentiated drug efficacy 
Patient needs prophylactic therapy size. 
 
Unnecessary drug therapy needs to be discontinued 
Drug used with no valid indication 
Patient ingested toxic amount of drug or chemical resulting in medical condition 
Drug  associated with drug abuse 
Patient with problem can be treated with non-drug therapy e.g. ,altering of life style 
Patient using multi-drug therapy for which single therapy is indicated 
Patient taking drug to avoid adverse reaction caused by another medication 
 
Wrong drug  
Drug not effective 
Patient allergy for this medication 
Patient receiving drug  not the most effective for that indication. 
Drug contraindicated 
Drug is not least costly 
Drug  not most safe 
Antibiotic used, organism involved  resistant to this drug 
Patient becomes refractory to  present drug therapy 
 
Dosage too low 
Dosage is too little to produce desirable effect. 
The drug serum level is below the therapeutic range. 
Length of time of prophylaxis is inadequate for this patient. 
Drug, dose, route, formulation conversion were inadequate. 
 
Adverse drug reaction 
Drug used administered too rapid. 
Patient has allergy for this drug. 
Patient has risk factor making this drug too harmful to be used. 
Patient has idiosyncratic reaction to this drug. 
Bioavailability of drug is altered by drug interaction. 
Efficacy of drug has been altered by enzyme inhibition/ activation due to another drug patient is 
taking (drug interaction) 
The effect of drug has been altered by food (drug-food  interaction) 
The effect of drug has been altered by displacement from binding site by another drug patient is 
taking (drug interaction). 
 
Dosage is too high 
Dosage is too high for this patient ( e.g. Elderly or baby) 
Patient serum level is above the desired therapeutic range. 
Patient is escalated too rapidly. 
Patient has accumulated drug from chronic use. 
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Compliance 
Error prescribing, dispensing, administration and monitoring. 
Patient is not adhering with instruction for using medication. 
Patient is not taking drug due to high cost 
Lack of understanding of the directions. 
Is not consistent with patient beliefs. 
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Appendix C: 
 
Pharmaceutical care issues (PCIs) and intervention categorisation used 
in our study 
 
1.Fail to receive drug 
Pharmaceutical care issue types                 
2.Untreated condition  
3.Improper drug selection 
4.Unwanted medication 
5.Drug used with no valid indication  
6.TDM  
7.Follow-up 
8.Compliance  
9.Inability to self-medicate 
10.Assess patient problem 
11.Sub-therapeutic dose 
12.Over dose 
13.Adverse reaction 
14.Drug Interaction 
15.Efficacy of medication 
16.Poor knowledge 
17.Prescriber problem 
18.Social problem 
19.Cost effectiveness 
20.Other 
1. Monitoring                            
Intervention types  
2. Counselling                              
3. Assess indication                     
4. Review medications                    
5. Switch to other medication             
6. Change dose                             
7. Change duration                         
8. Change frequency                      
9. Discontinue unwanted medications 
10. Add new medication 
11. Change medication  formulation                 
12. Change time of administration       
13. Contact health care provider    
14. Others                               
15. No intervention 
16. Data not sufficient to classify the intervention 
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Appendix D: 
 
Descriptions of pharmaceutical care issues 
 
Pharmaceutical care 
issues   
Description 
1.Fail to receive drug Patient has medical problem resulting from his or her not receiving 
drug. 
 
2.Untreated condition Patient has a medical problem requiring drug therapy (indication for 
drug use) but not receiving drug for that indication. 
 
3.Improper drug selection Patient has medical condition through taking wrong drug. not 
effective for that indication, patient has allergy for that medication., 
not the most effective for that indication, drug contraindicated, drug 
is not least costly, not the most safe, patient has an infection with 
organism involved resistant to this drug, or patient receiving 
combination product when single therapy would be more 
appropriate. 
4.Unwanted medication Patient use  can be associated with drug abuse ,medical problems 
can be treated with no drug therapy or the patient is taking multiple 
therapy for  a condition for which only single drug therapy is 
indicated 
5.Drug used with no valid 
indication 
Patient taking drug for which no medically valid indication. 
 
6.Follow-up Patient has medical condition needing  to follow progress 
7.Compliance (Adherence) Patient did not comply (adherence) with the recommended 
directions for using medication may be due to high cost, lack of 
understanding of directions or not being consistent with patient’s 
health beliefs. 
8.Assess patient problem Patient has medical problem on medication for long period, need to 
assess drug. 
9.Sub-therapeutic dose Patient problem is being treated with too little of correct drug. Or the 
dosage used too low to produce  desired response for this patient or 
serum drug concentration is below desired therapeutic range 
 
10.Over dose Patient has medical problem being treated with too much of correct 
drug. 
11.Adverse reaction Patient has medical problem resulting from adverse reaction to drug 
or drug was administered too rapidly for this patient or patient is 
having allergic reaction to  this drug 
12.Drug interaction The patient has a medical problem that is the result of a drug-drug or 
drug-food interaction. 
13.Efficacy of medication Patient taking medication for correct indication , but without 
positive outcome, e.g. sub-therapeutic dose 
14.Poor knowledge Patient medical condition due to poor knowledge about his/her 
medications or proper use of drug. 
15.Prescriber problem PCIs caused by prescriber, such as physician on holiday or 
appointment cancelled, not all medication issued or quantity not 
enough. 
16.Social problem Patient with social problem may result in poor compliance 
17.Cost effectiveness Patient medicine can be changed to other cheaper formulation or 
medicine. 
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Appendix E: 
 
Descriptions of intervention categories 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Intervention Types Description 
1. Monitoring Monitor medication efficacy, adverse effects and progress or 
improve symptoms by using subjective or objective 
measurements 
2. Counselling Educate and train patient or caregiver about medications, e.g. 
using inhaler drugs 
3. Review medications Exclude unwanted, unnecessary, expired and non-valid 
indication medications. 
4 Switch to other medication Switch to other medication for same indication for efficacy, price 
or other reason 
5. Change dose Recommend to physician to correct improper dose 
6. Change duration Recommend to physician to correct improper duration of 
treatment 
7. Change frequency Recommend to physician to correct improper dose frequency 
8. Discontinue unwanted 
medications. 
Recommend to physician to discontinue one or more of 
medications because no valid indication, or  efficacy issue or 
adverse effects 
9. Add new medication Patient requires new drug therapy to treat new illness or addition 
of second or third drug to treat a condition optimally 
10. Change medication form Recommend to physician or patient to change medicine 
formulation for efficacy, cost effectiveness or other reasons 
11. Change time of administration Recommend to physician or patient to change time of drug 
administration for convenience of patient, time or other reasons 
12. Solve supply issue Pharmacist Solve patient supply problems, coordinate with other 
health providers. 
13. Contact health care provider Pharmacist contact doctor, nurse or other care providers to 
discuss or solve patient problems 
14. Others Not included in our classification 
15.No intervention No further intervention required or CP detects PCI and no action  
taken to solve it 
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Appendix F: 
 
Designed data collection form in Microsoft Access by researcher 
 
 
 
 
 
 
 
  
1 
2 
3 
4 
5 
Etc. 
 
 
Month 
1. Monitoring.                            
2. Counselling.                              
3. Assess indication.                     
4. Review medications.                    
5. Switch to other medication.             
6. Change dose.                             
7. Change duration.                         
8. Change Frequency.                        
9. Discontinue Unwanted medications.       
10. Add new medication.204                    
11. Change Med. form. 29                 
12. Change time of administration.       
13. Solve supply Issue.62             . 
14. Contact health care provider.195      
15. Others.                               
16  No intervention 
 
Intervention types 
1-Pharmacist 
2-GP  
3-Nurse 
4-Patient 
5-Pharmacist and GP. 
Etc. 
 
1 
2 
3 
4 
5 
Etc 
 
Score  
The panel classification 
 1. Detrimental to the management of the patient. 
2. Improved the efficacy of therapeutic management. 
3. Prevented harm to the patient. 
4. Prevented a hospital admission. 
5. Information ( no clinical issue) 
6. No information available to classify the 
 
1. Fail to receive drug 
2. Untreated condition   
3. Improper drug selection 
4. Unwanted medication 
5. Drug used with no valid 
indication  
6. TDM  
7. Follow-up 
8. Compliance  
9. Inability to self-medicate 
10. Assess patient problem. 
Etc. 
 
 
PCIs types 
Person involved 
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Appendix G: 
 
Frequencies of Pharmaceutical care issues 
 
 
 
Pharmaceutical care issues types Frequency % 
Efficacy of medication 527 18% 
Adverse reaction 485 17% 
Untreated condition 357 12% 
Follow up 299 10% 
Assess patient problem 271 9% 
Compliance issue 257 9% 
Unwanted medication 167 6% 
Poor knowledge 113 4% 
Prescriber problem 68 2% 
High dose 65 2% 
Sub-therapeutic dose 61 2% 
Drug interaction 50 2% 
Drug used with no valid indication 40 1% 
Therapeutic drug monitoring (TDM) 36 1% 
Cost effectiveness 23 1% 
Others 18 1% 
Fail to receive drug 16 1% 
Improper drug selection 16 1% 
Inability to self medicate 6 0% 
Social problem 4 0% 
Total 2879 100% 
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Appendix H: 
  
Frequencies and percentages of pharmaceutical care issues in each 
month of study 
 
Months Frequency % 
1 692 24% 
2 414 14% 
3 329 11% 
4 277 10% 
5 205 7% 
6 172 6% 
7 155 5% 
8 166 6% 
9 135 5% 
10 131 5% 
11 98 3% 
12 105 4% 
Total 2879 100 
 
 
 
 
 
 
Appendix I:   
  
Frequency of "pharmaceutical care issues" in each of study intervals 
 
 
 
Period point No. % 
T1 1435 50% 
T2 655 23% 
T3 456 16% 
T4 333 12% 
Total 2879 100% 
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Appendix J : 
Monitoring sub-categories 
Monitoring subcategory No. % 
Bio-chemical 286 31% 
Objective 156 17% 
Subjective 447 48% 
Follow up 29 3% 
Therapeutic drug monitoring ( TDM) 5 1% 
Others 4 1% 
Total 927 100% 
 
 
Appendix K: 
Counselling sub-categories 
 
Counselling types No. % 
Drug information 119 41% 
Drug compliance 42 15% 
Compliance aid 20 7% 
Training on inhaler used 37 13% 
Others 70 25% 
Total 289 100% 
 
Appendix L: 
Referral to other health care provider sub-categories 
Health care providers No. % 
General practitioners (GPs) 133 70% 
Nurse 23 12% 
Others 33 18% 
Total 189 100% 
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Appendix M:  
   
GP Implementation of community pharmacists' recommendation 
including two categories "Not enough information" and "Not 
applicable" 
 
Intervention Code Yes No Not enough information 
Not 
applicable 
Add new medication 138 36 19 5 
Assess indication 14 2 40  
Change dose 164 52 31 1 
Change duration 0 0 1 0 
Change Frequency 33 1 15 0 
Change medication form 24 6 2 0 
Change time of administration 7 -- 5 1 
Contact health care provider 9 2 161 14 
Counselling 12 2 265 23 
Discontinue Unwanted medication 93 28 8  
Monitoring 78 9 853 8 
no intervention 0 0 0 343 
Others 6 3 25 10 
Review medications 15 2 95 0 
Solve supply Issue 20 0 37 6 
Switch to other medication 102 32 17 0 
Grand Total 715 175 1574 411 
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Appendix N: 
 
SPSS Drugs list shows only a) drugs name, b) strength, c) formulation 
and d) time intervals 
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Appendix O: 
 
Accepted and non-accepted community pharmacist’s recommendation 
in RESPECT study of therapeutic change regimen categories 
 
Therapeutic change regimen categories Accepted recommendation Not accepted 
No. % No. % 
Add new medication 138 26% 36 23% 
Change dose  164 31% 52 34% 
Change medication formulation 24 5% 6 4% 
Discontinue Unwanted medication 93 18% 28 18% 
Switch to other medication 102 20% 32 21% 
Total 521 100% 154 100% 
 
 
  
Appendix P: 
 
Researcher re-categorisation of community pharmacist interventions 
in RESPECT study using Hawksworth et al.,(1999) 
 
Researcher ranking Frequency % 
Prevented hospital admission 84 3% 
Prevented harm to patient 1015 35% 
Improved efficacy of management 1081 38% 
Detrimental to management 79 3% 
Information 312 11% 
Insufficient information to classify  308 11% 
Total 2879 100% 
 
 
 
Appendix Q: 
 
Yes/ No options gained by the clinical panel for the category 
'intervention for information only' 
 
Information options Frequency % 
Yes 338 12% 
No 2541 88% 
Total 2879 100% 
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Appendix R: 
 
Reason for interventions (PCIs) correlate with pharmacist intervention 
scoring which could prevent hospital admission 
 
PCIs Improve efficacy  score ≥7 
Prevented harm 
 Score ≥ 7 Total 
Adverse reaction 80 7 87 
Assess patient problem 17 7 24 
Compliance Issue 10 28 38 
Cost effectiveness 1   
Drug Interaction 21 1 22 
Drug used with no valid indication 4 3 7 
Efficacy of medication 17 19 36 
Fail to receive drug 5 1 6 
Follow up 5 3 8 
Improper drug selection 3 1 4 
Inability to self medicate 1 0 1 
Other 1 2 3 
Over dose 16 3 19 
Poor knowledge 5 8 13 
Prescriber problem 4 0 4 
Social problem  12 12 
Sub-therapeutic dose 3 0 3 
TDM 1 4 5 
Untreated condition 36 6 42 
Unwanted medication 32 0 32 
Grand Total 262 103 367 
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Appendix S: 
 
Pharmacist intervention frequencies classified by the clinical panel as 
intervention could prevent hospital admission 
 
Intervention type Improve efficacy score ≥7 
Prevented harm 
score≥ 7 
Total 
Add new medication 9 32 41 
Assess indication 5 2 7 
Change dose 18 47 65 
Change Frequency 4  4 
Change medication form 7 7 14 
Change time of administration 1 2 3 
Contact health care provider 3 22 25 
Counselling 22 20 42 
Discontinue unwanted medications 5 41 46 
Monitoring 9 45 54 
no intervention  0 0 
Others 4 5 9 
Review medications 10 7 17 
Solve supply Issue  5 5 
Switch to other medication 6 29 35 
Grand Total 103 264 367 
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Appendix T: 
 
Percentage of drugs involved in RESPECT study according to BNF 
classification after excluding patient's duplication 
 
 
 
 
 
 
 
 
BNF classification Category % 
Category 1 Gastro-intestinal system 9.917 
Category 2 Cardiovascular systems 34.269 
Category 3 Respiratory System 6.586 
Category 4 Central nervous system 18.827 
Category 5 Infections 0.877 
Category 6 Endocrine system 6.693 
Category 7 Obstetrics, gynaecology and urinary tract disorders 1.169 
Category 8 Malignant disease and immunosuppressant 0.015 
Category 9 Nutrition and blood 7.686 
Category 10 Musculoskeletal and joint disease 8.663 
Category 11 Eye 3.316 
Category 12 Ear, nose, and oropharynx 0.046 
Category 13 Skin 0.0307 
Total  100 
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Appendix U: 
 
   Drugs most commonly prescribed in RESPECT study according to 
SPSS drug list provided by RESPECT study team 
 
Drugs Percentage 
Aspirin 4% 
Atenolol 3% 
Warfarin Sodium 3% 
Simvastatin 3% 
Aspirin E/C 3% 
Furosemide 3% 
Paracetamol 3% 
Bendrofluazide 2% 
Isosorbide Mononitrate 2% 
Thyroxine 2% 
Co-Codamol 2% 
Atorvastatin 2% 
Co-Proxamol 2% 
Digoxin 2% 
Amlodipine Besilate 1% 
Ramipril 1% 
Glyceryl Trinitrate 1% 
Salbutamol CfC-Free 1% 
Omeprazole 1% 
Lansoprazole 1% 
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Appendix V: 
 
New condensed classification of PCIs by researcher 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pharmaceutical care issue types Frequency Percentage 
Fail to receive drug 373 13% 
Wrong dose 126 4% 
Adverse reaction 485 17% 
Drug Interaction 50 2% 
Efficacy of medication 527 18% 
Poor knowledge 113 4% 
Cost effectiveness 23 1% 
Others 89 3% 
Improper drug selection 16 1% 
Unwanted medication 167 6% 
Drug used with no valid indication 40 1% 
Monitoring required 606 21% 
Compliance  264 9% 
Total 2879 100% 
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• Patient 
• Disease  
• Drug 
Pharmacist ensures of patient:- 
• Understanding 
• Expectation 
• Concerns  
• Behaviour  
Patient information’s  Pharmacist interpretation 
• Indication 
• Efficacy 
• Safety 
• Compliance 
New pharmaceutical care issues detected  
Yes 
 
No 
• Resolve pharmaceutical care issues 
• Meet treatment goals 
• Prevent any expected PCIs 
 
 
Outcomes Interventions 
 
Goals treatment met for this 
condition 
 
 
 
Appendix W: 
 
Continuous process of pharmaceutical care 
 
 
 
 
 
 Adapted from Cipolle et al, (1998) 
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Appendix X: 
 
Classification of PCIs in RESPECT study as by AbuRuz et al.,(2006) 
classification 
 
 
 
Pharmaceutical 
care issues 
Frequency Percentage Sub-classification Frequency 
Indication 851 29.56 Assess patient problem 271 
   Drug used with no valid indication 40 
Unwanted medication 167 
Untreated condition 357 
Improper drug selection 16 
Total 851 
Efficacy 653 22.68 Efficacy of medication 527 
   high dose 65 
Low dose 61 
Total 653 
Safety 551 19.14 Adverse reactions 485 
   Fail to receive drug 16 
Drugs interaction 50 
Total 551 
Compliance 257 8.92 adherence  to instruction 257 
     
Poor knowledge 113 3.92 Inappropriate knowledge 113 
   
Follow up 335 11.64 Follow up lab and others monitoring types 299 
  TDM 36 
Total 335 
Miscellaneous 118 4.10 Prescriber problem( poor communication) 68 
Total 2878 100 Inability to self medicate 6 
   cost effectiveness 23 
Social problems 4 
Others 17 
Total 118 
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Appendix Y: 
 
Missing data, means and standard deviation of regular drugs prescribed including 
T5 (Table 2) and after excluding T5 (Table 4) for the 346 patient in SPSS drug list  
 
Table (1) Missing data of our study patients (For 346 patients were chosen after 
excluded 52 of total of 398 patient) on SPSS drugs list. 
 
Patients not in the SPSS drug  list and include in our study  =27 patients 
Patients with missing T5=52 patients 
Patients with missing T1,T2,T3=5 patients 
  
 
Table (2) the number of regular drugs dispensed to our study patients (319 after 
excluding 27 patients which who were missing from the drug list) in each of study 
intervals (T1, T2, T3, T4 and T5) 
 
Study interval  T1 T2 T3 T4 T5 Total 
Total 2348 2406 2478 2591 1890 11713 
 
Table (3) Standard deviation and average of regular drugs dispensed for 319 patients 
included in our study according to SPSS drug list 
 
 
 
 
Table (4) the number of regular drugs dispensed to our study patients (319) in each of 
study intervals (T1, T2, T3, T4 and excluding T5) 
 
Study interval  T1 T2 T3 T4 Total 
Total 2348 2406 2478 2591 9823 
 
 
Table (3) Standard deviation and average of regular drugs dispensed for 319 patients 
included in our study according to SPSS drug list (T1, T2, T3, T4 and excluding T5) 
 
 
 
 
 
 
 
 
 
Standard deviation of total drugs prescribed for each patient   12.38 
Average of total drugs prescribed for each patient  35.88 
Standard deviation of total drugs prescribed for each patient   10.38 
Average of total drugs prescribed for each patient  30 
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Appendix Z: 
 
Test of normality of drugs prescribed throughout the four intervals 
(T1, T2, T3 and T4) 
 
 
Table (1) Tests of Normality 
 
  Kolmogorov-Smirnov(a) 
  Statistic df Sig. 
T1 .133 319 .000 
T2 .136 319 .000 
T3 .118 319 .000 
T4 .136 319 .000 
                          a  Lilliefors Significance Correction 
 
 
 
 
 
Table 2 P-value between T1, T2, T3 and T4 
 
Source of Variation P-value  
P-value between T1,T2, T3 and T4.( between 
groups and with groups 
0.002714 
  
 
Table 3 Correlation in drugs prescribed in T1, T2, T3 and T4 
 
   T1 T2 T3 T4 
T1 Pearson Correlation 1 .751(**) .760(**) .595(**) 
Sig. (2-tailed)   .000 .000 .000 
N 319 319 319 319 
T2 Pearson Correlation .751(**) 1 .889(**) .686(**) 
Sig. (2-tailed) .000   .000 .000 
N 319 319 319 319 
T3 Pearson Correlation .760(**) .889(**) 1 .723(**) 
Sig. (2-tailed) .000 .000   .000 
N 319 319 319 319 
T4 Pearson Correlation .595(**) .686(**) .723(**) 1 
Sig. (2-tailed) .000 .000 .000   
N 319 319 319 319 
** Correlation is significant at the 0.01 level (2-tailed). 
 
 
 
 
Conclusion: Table 2 and 3, Results of ANOVA single factor in Excel and SPSS indicate 
that the data is not normal (i.e. there is significant differences between the drugs 
prescribed in the four intervals (T1, T2, T3 and T4) 
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Appendix AA: 
 
Percentage of drug types most commonly prescribed in the RESPECT 
study according to BNF subcategories 
 
 
 
 
 
 
 
 
BNF- sub-categories  Percentage  
Cardiovascular system drugs 38% 
Non steroidal anti-inflammatory drugs  10% 
Gastro intestinal tract 10% 
Asthma 7% 
Analgesic 7% 
Hormonal replacement therapy  5% 
Ophthalmic preparation 3% 
Anticoagulant 2% 
Psychiatry drugs 2% 
Hypoglycaemic  2% 
Skin 2% 
Nutrition and blood 2% 
Hypnotic 2% 
Muscle relaxant 2% 
Corticosteroid 1% 
Gout drug 1% 
Calcium supplement 1% 
Urinary tract  1% 
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Appendix AB: 
 
Assumed intervention types by Clinical panel with suitable related re-
categorisation using Hawksworth, (1998) 
 
 
 
 
 
 
Prevented hospital admission 
• Decrease number of days to stay at hospital 
• Decrease GP visit 
• Overdose 
• Duplication 
• Wrong medication 
 
2) Prevented harm to patient    
• Add new medication to prevent harm or disease 
• Switch to other medications 
• Monitoring blood pressure , biochemical profile , disease  progress, U/E  etc. 
• Reduce side effects 
• Reduce drug interaction 
 
3) Improved efficacy of management. 
• Change dose.( Increase or decrease dose  because symptoms improved) 
• Improve compliance. 
• Counselling patient (educate patient how to use devices e.g. inhaler and stick 
devices). 
• Review medication 
• Assess drug indication. 
• Follow-up e.g. test blood or measure blood pressure 
• Monitor medication efficacy 
• Discontinue dose because is not effective 
• Recommend continued use of drug 
 
4) Information only 
• Refer to general practitioner (or other HCPs). 
• Cost effectiveness 
• Change the drug brand 
• Prescription legality 
• Outcome 
 
5) Detrimental to patient management.   
• Pharmacist recommended drug induces side effects. 
• Initiating unrequited drug. 
• Using herbal medication. 
• Doing nothing. 
• Discontinue without good reason just because used for long period. 
• Prescribed drug may cause harm to patient, e.g. Nitrazepam. 
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Appendix AC: 
 
Community pharmacy contribution in care of patients with long-term 
conditions (LTCs) 
 
 
 
 
 
 
Community pharmacy contribution in care of people with long-term conditions,  
Source:  adapted from Department of Health Care in NHS (2008). 
 
Level 1 (supported self care
• Health promotion and counselling. 
) 
• Practical help with appropriate medicine use, such as compliance aids. 
• Advising on the appropriate use of over the counter medication (OTC), for 
example for pain 
 
 
• Promptly detecting poor control of conditions, e.g. a person with asthma 
returning frequently for asthma reliever inhaler. 
Level 2 (specialist disease care) 
• Identifying high risk patient and initiating action to prevent deterioration. 
• Helping people to optimise their medicine use, through group education. One to 
one counselling. 
• Regular monitoring of condition. 
• Supplementary prescribing within clinical guidelines. 
• Pharmacists with a special interest as disease- specific care managers. 
 
 
• Helping to reduced hospital admissions through community medicine 
management (MM) 
Level 3 (Case management) 
• Ensure safe hospital discharge by providing medicines support in the community. 
• Pharmacists mentoring advanced primary care nurses or acting as Advance 
primary practitioners 
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Appendix AD: 
 
Pharmaceutical care issues determined by pharmacists and 
interventions to solve them
  158 
  
 
 
 
PCIs 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Total 
1 4 2  1 2    1     4  2 16 
2 68 31 3 2 2 5  2  97   1 70 6 70 357 
3 1 2   5    2 5      1 16 
4 29 7 8 8 14 27  13 38 5 1  1 4 1 11 167 
5 1  9 5 2    10 2  1  2  8 40 
6 30 1    1    1      3 36 
7 168 10 1 27  2    5   5 13 5 63 299 
8 40 74 3 6 11 10  15 4 5 13 3 13 16 12 32 257 
9  1    1        2 1 1 6 
10 158 3 18 13 5 8   9 17    16 5 19 271 
11 4   1 1 46  4   2   1  2 61 
12 9 1  1  43  4 2    1 2  2 65 
13 156 38 9 14 61 53 1 6 46 33 5 5  16 7 35 485 
14 14 6  4 10 1  2 6 1    2 1 3 50 
15 226 32 3 24 32 48  5 9 30 5 2 3 23 3 82 527 
16 5 70 1 4  3   2   4 1 11 2 10 113 
17 8 3  1  1    1   33 7  14 68 
18 1 1             2  4 
19 3 2 1 2 6 1   1  6    1  23 
20 2 3   1 1       5  2 3 17 
                  1 
Total 927 287 56 113 152 251 1 51 130 202 32 15 63 189 48 361 2879 
Pharmaceutical care issues 
1=Fail to receive drug 
2=Untreated condition  
3=Improper drug selection 
4=Unwanted medication 
5=Drug used with no valid 
indication  
6=TDM  
7=Follow-up 
8=Compliance  
9=Inability to self-medicate 
10=Assess patient problem 
11=Sub-therapeutic dose 
12=Overdose 
13=Adverse reaction 
14=Drug interaction 
15=Efficacy of medication 
16=Poor knowledge 
17=Prescriber problem 
18=Social problem 
19=Cost effectiveness 
20=Other 
Intervention types 
1= Monitoring.                            
2= Counselling.                              
3= Assess indication.                     
4=Review medications.                    
5=Switch to other medication.             
6= Change dose.                             
7= Change duration.                         
8= Change frequency.                        
9= Discontinue unwanted medications. 
10=Add new medication. 
11=Change medicine formulation.                 
12= Change time of administration.       
13= Solve supply Issue.            . 
14. Contact health care provider.    
15= Others.                               
16= No intervention 
Intervention types 
PCIs 
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Appendix AE: 
 
Frequency and percentage of pharmaceutical care issues and 
interventions in every month of study period 
 
Month PCIs  Frequency % 
Interventions 
Frequency % 
1 692 24% 597 24% 
2 414 14% 372 15% 
3 329 11% 287 11% 
4 277 10% 244 10% 
5 205 7% 178 7% 
6 172 6% 153 6% 
7 155 5% 135 5% 
8 166 6% 147 6% 
9 135 5% 119 5% 
10 131 5% 107 4% 
11 98 3% 84 3% 
12 105 4% 95 4% 
Total 2879 100% 2518 100% 
 
 
 
 
 
 
 
 
 
 
  160 
Appendix AF: 
 
Accepted and non-accepted CP recommendations by GPs in 
RESPECT study after excluding: a) no information and b) not 
applicable 
 
 
 
 
 
 
 
 
Implementation No. % 
Yes 715 80% 
No 175 20% 
Total 890 100% 
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Appendix AG: 
 
Examples of approved pharmacist parametric measurement follow-up 
sheets to improve pharmacist documentation in future study 
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Primary care clinical skill programme 
 
Patient_ ID: ---------------------------------- Age:  --------------------------------------------------------- 
Physical assessment / Laboratory data Initial / Follow up 
Date         
Height        
Weight         
Temp        
BP        
Pulse        
Respiration        
Peak flow         
FBG        
R. Glucose        
Hba1c        
T. cholesterol        
LDL        
HDL        
TG        
INR        
BUN        
Cr        
ALT        
AST        
ALK Phos        
Drug serum concentration ( Therapeutic Drug Monitoring)(TDM)) 
Date         
Drug 1        
Drug 2        
Source: American Society of Health System Pharmacists (2000) 
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Pharmacists Care Plan Ambulatory Monitoring Worksheet (AMW) 
 
 
                Patient name: -------------------------. Pharmacists: ------------------------. Date: ---------------------.  
 
Pharmacotherapeutic Goal 
 
Monitoring Parameter Desired  
Endpoint 
Monitoring Frequency 
Date        
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
Source: American Society of Health System Pharmacists (2000) 
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Ambulatory Pharmacists Care plan 
 
         Patient name: -------------------------. Pharmacists: ------------------------. Date: ---------------. 
 
Date 
identified 
PCIs Pharmacotherapeutic 
and related care goal  
Recommendation for 
therapy 
Monitoring 
parameters 
Desired Endpoint Monitoring 
Frequency 
       
       
       
       
       
       
       
       
       
       
       
       
       
       
 
Source: Adopted from American society of Health system 
Pharmacists (2000) 
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Appendix AH: 
 
The means, standard deviation and variance results of pharmaceutical 
care plans frequency for patients included                                  in our 
study (346) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total No. of patients chosen in the study 398 
No. excluded patients  52 
Total number of pharmaceutical care plans (PCPs) 3056 
Mean of No. of PCPs numbers 8.85 
Std dev. 3.268 
Variance 10.68 
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